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ABSTRACT 
Clinical Implications for Mitochondrial Stress Induced Senescence and Potential 
Interventions 
Ashley Azar 
Christian Sell, PhD 
 
 
Understanding the mechanisms behind how cells and organisms age is of great 
importance when trying to develop therapies to combat multiple age-related 
disorders without the need for excessive prescription medications. One context 
where age related disorders are prevalent is in patients suffering from HIV-1 
infection. These patients, even when on antiretroviral therapies, exhibit multiple 
signs of premature aging, one of which includes HIV-associated neurocognitive 
decline. Deficits in these patients are thought to be due to a combination of viral 
infection and long-term antiretroviral treatment. Antiretroviral drugs are known to 
induce mitochondrial damage, which may be responsible for driving comorbidities in 
this population. Further analysis of the impact of drugs on mitochondria is required to 
fully elucidate toxicity and develop adjuvant therapies. In addition, these patients 
exhibit a large degree of heterogeneity in the severity of side effects that is still not 
well understood. In order to understand these dynamic interactions, we set out to 
determine if mitochondrial genetic backgrounds can influence neurocognitive 
heterogeneity, determine the mitochondrial and cellular effect of antiretrovirals and 
identify potential therapeutics that can help combat cellular dysfunction and provide 
relief for patients suffering from age related diseases.  
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CHAPTER 1: INTRODUCTION  
 
1.1 What is Aging and Why is it an Important Research Field? 
 
The most accurate definition of the aging process is an increasing inability for 
an organism to maintain homeostasis in multiple organs systems, giving rise to an 
increased vulnerability to disease. Data from the Centers for Disease Control and 
Prevention support this definition. In Figure 1.1, number of deaths from cancer, heart 
disease, chronic respiratory disease, cerebrovascular disease and unintentional 
death are plotted as a function of age. Deaths from these diseases increase sharply 
in middle age (45-55 year of age) and rise progressively thereafter, reflecting the 
greater vulnerability to multiple diseases throughout the aging process. The inability 
to maintain homeostasis, which contributes to this vulnerability, is evident in the 
example of age-related changes in cardiac and brain function. The decreased 
compliance of cardiac tissue and the shrinking of brain tissue are excellent examples 
of the reduced dynamic capacity that characterizes aged organisms. Underlying the 
differences in functional parameters are changes in cardiac and brain architecture 
due to intrinsic aging [1,2]. These changes lead to reduced function that requires 
compensation to maintain normal physiology. Age-related changes and 
compensatory responses become more pronounced with age, eventually producing 
the greater vulnerability to disease depicted by the curves in Figure 1.1. Similar 
change occurs in all organ systems as a function of age, resulting in the eventual 
loss of dynamic range and lack of compensatory response typical of the aged 
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organism [3]. For this reason, studying the mechanisms behind why and how 
organisms age is vastly important for understanding the triggers for the large number 
of diseases that are brought on by old age. These aging triggers once defined will 
provide a platform to create therapeutics that target multiple diseases and promote 
healthy aging. 
 
Figure 1.1.  CDC leading causes of death toll with age.   
2015 CDC data curves showing the number of deaths cause by 6 leading causes as a 
function of age.  
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1.2 Biologic Versus Chronologic Age 
 
Variation in the rate and degree to which organisms age suggests that 
chronologic age may not be the best nor the most clinically relevant measure of the 
age of an individual. Therefore, efforts have been undertaken to identify biomarkers 
that can be used to assess the true age of an individual. Though these efforts have 
not yet produced any marker or group of markers that can serve this purpose to the 
satisfaction of the scientific community, the National Institutes on Aging continue to 
support efforts to define biomarkers of aging for their potential clinical impact [4]. In 
addition, large-scale genetic analyses of populations that possess exceptional 
longevity have been underway to understand individual differences in the rate of 
aging [3]. Groups like the Einstein Ashkenazi Longevity Study in New York, the New 
England Centenarian Study at Harvard and the Southern Italian Centenarian Study 
have each enrolled several hundred individuals. Thus far, these groups and others 
have identified polymorphisms associated with longevity in the ApoE, FOXO3A, 
DRD4, IGF receptor, and Lamin A genes [5-9]. Continued work on genetic 
association with age are on going and have the potential to provide vast insight on 
the regulation of aging prcosses.  
 
1.3 Theories of Aging 
 
Multiple theories of aging have been proposed. Some suggest that specific 
types of damage, such as DNA damage or mitochondrial dysfunction drive the aging 
  
4
process, whereas others examine aging from an evolutionary perspective. The most 
general question regarding aging is why organisms age at all. In 1889, August 
Wiesmann made the observation that aging is a property of the somatic tissues and 
not the germline, which possesses an unlimited capacity for self-renewal. The 
concept Weismann developed stands on two principles; first, that the germline is 
immortal while the somatic cells are mortal and second, that aging allows for the 
removal of older individuals to make space for the next generation [10].  A synthesis 
of evolutionary theory and the aging process by Peter Medawar in 1952 led to the 
concept that aging is not under selective pressure, since reproduction occurs 
relatively early in life and few organisms in the wild live to advanced age. Thus, 
aging as a phenomenon is restricted to protected environments and is likely due to 
an inability to repair damage beyond the reproductive phase of life [11].  The 
concept that aging occurs in post reproductive organisms has led to the theory of 
antagonistic pleiotropy [12].  This theory states that mutations that benefit an 
organism early in life may have negative effects later in life. According to 
antagonistic pleiotropy, mutations that increase reproductive fitness may contribute 
to age-related declines in the same organism. For example, a rapid developmental 
rate may enhance reproductive fitness in a subset of organisms within a population, 
but this advantage may lead to increased cancer risk in these individuals as they 
age.  
Building upon the concept of a tradeoff between fitness and longevity inherent 
in the aforementioned theories and based upon the idea that an organism must 
allocate limiting resources to either maintenance or longevity, Thomas Kirkwood 
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developed the disposable soma theory of aging [13].  The disposable soma theory 
postulates that insufficient energy is available to the organism for the maintenance of 
both germline and soma, forcing an allocation of resources that leads to the eventual 
deterioration of the somatic tissues. The theory has traditionally centered upon the 
allocation of energy in the form of ATP; however, we have developed the concept 
that time is the most likely limiting resource that constrains longevity [14,15].  In this 
iteration of the disposable soma theory, the time allotted for repair of genomic 
damage is limited due to evolutionary pressure; and it is time, rather than energy, 
that represents the limiting resource for an organism. 
Recently, the possibility that aging may be subject to a level of regulation has 
been put forth. Trivial arguments have been made based on the fact that single gene 
mutations can influence longevity, but more rigorous arguments come from 
population biologists [16].  These arguments propose that aging of individuals is an 
altruistic trait that may lead to enhanced overall fitness of the population [17]. 
Several theories proposing the accumulation of specific types of damage as a 
primary cause of aging have gained widespread attention. These theories are 
properly placed under the umbrella of the disposable soma theory as they deal with 
potential mechanisms whereby the soma may become dysfunctional with age. One 
of the more prominent of these wear and tear theories is the free radical theory of 
aging championed by Denham Harman in the 1950s. At this time, the role of the 
oxygen free radical as a mediator of radiation damage was discovered and it was 
postulated that the accumulation of free radical damage might underlie age-related 
functional decline [18].  Because mitochondria are believed to be the primary source 
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of free radicals within the cell, the free radical theory has been intertwined with the 
mitochondrial theory of aging, which postulates that mitochondrial-generated free 
radicals are a major contributor to age-related damage [19]. However, free radicals 
can be generated by other cellular organelles such as peroxisomes [20], and 
mutations inducing mitochondrial dysfunction have been found to increase with age, 
generating discussion of new roles for mitochondrial dysfunction in aging which is 
discussed further in section 1.6 and 1.7 [21].  Similarly, DNA damage has been put 
forth as the primary cause of aging [22].  There is evidence for an accumulation of 
DNA damage with age [23] and mutations that decrease DNA repair capacity induce 
premature aging, but it has recently become clear that DNA damage responses are 
more important in aging than DNA damage per se [24].  Arguments have been made 
implicating other types of damage, such as glycation end products caused by non-
enzymatic protein linkage of carbohydrates, as primary drivers of aging. Taken 
together these theories suggest it is likely the balance between the accumulation of 
damage to macromolecules or organelles, and the integrity of the complex repair 
and clearance mechanisms that dictate the aging process [3]. 
 
1.4 Cellular Senescence as a Contributor to Aging 
 
Senescence is a cellular stress response triggered by insults that include 
oxidative and genotoxic stress, telomere attrition, and dysregulated mitogenic 
signaling. In mammals, the response is typically mediated through two pathways, the 
p53/p21CIP1/WAF1 and p16INK4A/Rb pathways, which appear to establish senescence 
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with different kinetics [25-28]. The DNA damage response pathway generally 
mediates the initial response by increasing levels of p21CIP1/WAF1; only at later times 
is senescence reinforced by expression of p16INK4A/RB.[27,29]  
The senescent state is characterized by significant changes in cell 
morphology and activity. Senescent cells are typically larger in size,[30] and exhibit 
increased activity of the lysosomal senescence-associated β-galactosidase,[31] 
persistent DNA-damage response signaling, DNA damage foci (telomere-
dysfunction–induced foci known as TIFs),[28,32,33] chromatin rearrangements and 
formation of senescence-associated heterochromatin foci (SAHF),[34] and loss of 
lamin B1 expression [35]. Leonard Hayflick was one of the first scientists to discover 
that human primary diploid cells grown in-vitro have a finite capacity to undergo 
population doublings [30]. It was discovered that this classical plateau in cell 
proliferation was triggered by continuous telomere shortening with repeated rounds 
of the cell cycle [28,32,33]. This shortening eventually leads to persistent DNA 
damage and the canonical p53 signaling discussed previously. In addition, 
chromatin structure is known to extensively change in senescent cells, specifically 
proliferation-promoting genes are known to be incorporated into transcriptionally 
silent heterochromatin previously described as SAHF and partially explains the 
canonical cell cycle arrest that defines senescence [36]. 
Moreover, senescent cells have been shown to promote the proliferation of 
pre-neoplastic cell lines in vivo [37]. The senescence-associated secretory 
phenotype (SASP), which contains pro-inflammatory cytokines, matrix 
metalloproteases, and growth factors may contribute to cancer progression and 
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metastasis, as well as neurodegenerative disorders, inflammatory disease, 
metabolic dysfunction, and other conditions that preferentially affect the 
elderly[25,38]. The expression of retinal pigmented epithelial differentiation factor, a 
key mediator of angiogenesis and stem cell survival also is decreased in senescent 
mesenchymal cells [3,39]. 
 Interestingly, a new class of drugs known as senolytics have been developed 
which specifically cause targeted cell death of senescent cells [40]. An example of 
this new tactic is the use of a genetic construct exploiting p16INK4A_ positivity to clear 
senescent cells. Preferentially clearing senescent cells has shown to ameliorate the 
premature aging phenotype in at least one progeroid mouse model (a model of a 
human disease associated with accelerated aging) [39]. These mice displayed 
delayed onset of lordokyphosis and cataracts as well as preserved muscle function 
and less adipose tissue loss. This suggests that the accumulation of senescent cells 
does indeed contribute to age-related pathologies and supports the importance of 
developing drug targets to eliminate or prevent senescence.  
 
1.5 Known Aging Interventions 
 
Interestingly, multiple interventions have been shown to delay senescence 
and increase the lifespan/healthspan of multiple organisms. Among these therapies 
are protein restriction and fasting mimetics, pharmacological inhibitors of the 
TOR/S6K pathway, pharmacological regulators of certain sirtuins, pharmacological 
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inhibitors of inflammation and chronic metformin [41]. Two specific regimens being 
tested with great promise are rapamycin and methionine restriction.  
Rapamycin, also known as Sirolimus, is a naturally occurring compound 
produced by bacteria first discovered on Easter Island. This compound originally 
named Rapa Nui after the native name of the island in which it was discovered was 
renamed rapamycin after its anti-proliferative properties were discovered and its 
ability to inhibit the TOR complex was identified. Rapamycin has been shown to 
delay senescence in-vitro in multiple cell lines including fibroblasts and epithelial 
cells as well as increase the lifespan of multiple organisms including mice, 
drosophila and C. Elegans [42]. Studies at three different test sites using genetically 
heterogeneous mice at 20 months of age showed a 14% lifespan extension for 
females and 9% lifespan extension for males when treated with rapamycin [42]. 
Through the inhibition of TOR, rapamycin reduces cell growth signaling and protein 
synthesis as well as increases the cells autophagy mechanisms. Our laboratory has 
shown that treatment of human fibroblasts with a nanomolar concentration of 
rapamycin, stimulates mitochondrial retrograde signaling to coordinate mitochondrial 
biogenesis with clearance, which results in extended replicative lifespan and 
resistance to mitochondrial stress [43,44].  Thus, improved mitochondrial 
homeostasis is a potential mechanism to delay or prevent cellular senescence. This 
isn’t surprising considering the discussion of the mitochondrial theory of aging 
discussed in section 1.3. 
Restricting the essential amino acid methionine in a diet with standard caloric 
content or in cell culture also improves both mitochondrial homeostasis, increases 
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lifespan and alters TOR signaling.  Rats fed a methionine restricted diet live up to 
45% longer than controls while mice enjoy a smaller but significant increase in 
lifespan combined with the amelioration of a number of age-related pathologies [45-
47].  At the cellular level, restricting methionine in culture media or genetically 
intervening with methionine synthesis delays cellular senescence, and extends 
replicative lifespan in human fibroblasts [48,49].  Similar to the benefits of rapamycin 
treatment, many studies have highlighted increased autophagy and improved 
mitochondrial and metabolic profiles following methionine restriction [50-54].  These 
results suggest that a possible mechanism for the lifespan-extending properties of 
both rapamycin treatment or methionine restriction is delayed cellular senescence 
due to improvements in mitochondrial function. 
 
1.6 Mitochondria and Aging 
 
Mitochondrial function is crucial for proper cellular function and homeostasis. 
Mitochondria serve to shuttle essential nutrients and provide fundamental energy 
machinery to the cell through processes like the Krebs cycle and oxidative 
phosphorylation. Molecules like ATP, NADPH and basic carbon skeletons are some 
of the fundamental resources used by the cell for maintenance and repair and all of 
these are produced in large portion by the mitochondria. Along with its role as an 
energy source, the mitochondria are central to multiple cellular processes. For 
example, mitochondria act as a calcium buffering system, an apoptosis mediator and 
a signaling hub through the production of ROS [55]. 
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Dysfunctional mitochondria have been shown to impact the aging process. A 
cell with dysfunctional mitochondria cannot effectively utilize nutrients to produce 
energy. Additionally, these cells produce excessive ROS that leads to downstream 
damage and global cellular dysfunction as described above briefly under the free 
radical theory of aging in section 1.3. It is also well known that mitochondrial 
function, primarily oxidative phosphorylation activity, declines with age and that 
mitochondrial DNA mutations accumulate with age [56]. It is proposed that 
accumulation of somatic mutations of mtDNA, induced by exposure to ROS, leads to 
errors in the mtDNA-encoded proteins; these errors are randomly transmitted during 
mitochondrial and cellular divisions. The consequence of these alterations 
exclusively affects the energy production of the ETC and oxidative phosphorylation. 
Respiratory chain defects are likely to produce increased ROS, thus, establishing a 
vicious circle of damage accumulation [57]. Clinically, mitochondrial dysfunction has 
been defined in multiple age related settings such as cardiovascular disease, 
neurodegenerative diseases, muscular degeneration etc [56]. Due to high-energy 
demands, certain tissues like the brain, heart and skeletal muscle are more severely 
affected by mitochondrial dysfunction [58,59].  One of the most common 
mitochondrial age-related deficits found in these tissues is the 4977bp mtDNA 
deletion also known as the “common deletion” [60]. This large deletion results in a 
reduction in the copy number of genes that fall within the deletion, which include 
subunits of ETC complexes I, IV and V. Another prime example demonstrating a 
potential connection between mitochondria and aging is the Polymerase-gamma 
mutator mouse. This mouse is a knock-in model with a mutated POLG gene creating 
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a polymerase with an alanine substitution for the critical aspartate (D257A). This 
mutation affects the second exonuclease domain and diminishes proofreading 
capabilities/mismatch repair mechanisms leading to a 3-5 times higher mtDNA 
mutation rate. These mice exhibit many signs of premature aging such as alopecia, 
kyphosis, hearing loss, osteoporosis, anemia, cardiac hypertrophy and shortened 
lifespan and are used as a progeroid model system [61]. This is a direct example of 
how merely altering normal mitochondrial DNA maintenance can cause a whole host 
of age related complication and shows that maintaining proper mitochondrial 
homeostasis and specifically mitochondria DNA maintenance is important in 
maintaining healthy aging and an important target for developing adjuvant therapies. 
 
1.7 Mitochondrial DNA 
 
The mitochondrial DNA (mtDNA) is a circular; double stranded genome 
stretching about 16,569 base pairs. mtDNA encodes for 13 proteins (all of which 
contribute to electron transport chain function), 2 rRNAs and 22 tRNAs. Figure 1.2 
panels B&C depict the mitochondrial genome and color coded gene loci in relation to 
their placement in the ETC [62]. A single eukaryotic cell can contain hundreds of 
mitochondria and each mitochondrion carries multiple copies of the mtDNA. This 
enormous amount of mtDNA is needed in order to combat the poor fidelity of the 
mitochondrial polymerase gamma, which has a mutation rate that is 10 times higher 
than the nuclear polymerases. This inherent poor fidelity represents an evolutionary 
advantage in order to introduce genetic variability in a given population and to 
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account for the fact that mtDNA has not been shown to undergo recombination [63]. 
Interestingly, mtDNA is strictly inherited through the maternal lineage. Sperm cells 
have relatively untraceable amounts of mtDNA so oocytes are considered the sole 
contributors of the mtDNA containing roughly 100 time more mtDNA per cell than 
sperm [58]. Evolutionary pressures have shaped the mitochondrial genome to 
include regional variations, known as haplogroups [58]. Figure 1.2 A depicts the 
migration and location of mitochondrial haplorgroups across the globe [64]. Among 
other metabolic changes, these mitochondrial haplogroups can shift mitochondrial 
output between ATP production and heat production by altering the coupling 
efficiency of the electron transport chain in response to environmental pressures, 
potentially providing distinct evolutionary advantages in different environmental 
niches [65]. From an evolutionary perspective, it has been proposed that 
haplogroups that arose in sub-Saharan Africa result in the production of ETC 
complexes that are more efficient as to lose less energy to heat in such warm 
climates as well as to provide the individual with the ability to produce the energy 
needed to run from predators. Conversely haplogroups evolved as Homo sapiens 
migrated to colder climates and had the need to acquire ETCs that lost energy to 
produce heat. This paradiagm has been verified in-vitro with studies where cybrids 
(transfer of mitochondrial variants onto a common nuclear genetic background) were 
created to compare L and H mitochondrial haplogroup backgrounds (African and 
European respectively) [66]. This study showed that the African haplogroup 
displayed decreased ATP turnover rates and lower levels of reactive oxygen species 
production, parameters which are consistent with more efficient oxidative 
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phosphorylation. Differences in coupling efficiency create a unique background in 
each mitochondrial haplogroup causing a distinct interaction with environmental 
toxins and nuclear influences. For example, a specific interaction between mutations 
causing Leber hereditary optic neuropathy (LHON) and mitochondrial haplogroups 
indicates that haplogroup J exacerbates this disease phenotype [67]. In addition, 
there is evidence that specific mtDNA haplogroups are correlated with successful 
aging. In particular, mtDNA haplogroup J has been associated with increased 
longevity in northern Italians, Northern Irish and Finns[68].  
The mtDNA replicates independently of the nuclear genome and mitochondria 
is passed on to daughter cells during division through segregation and cytokinesis. 
This results in cells that have varying ratios of different mtDNAs this phenomenon is 
known as heteroplasmy. Given an individual may have a “good” mtDNA population 
and a “bad” mtDNA population, the ratio at which they are present in a cell can 
determine cell phenotype. It appears that the “bad” mtDNA needs to be present at 
over ~60-80% in order for the detrimental phenotype to manifest, this concept is 
known as the threshold effect [64]. The most common example of this is patients 
with the neurological and neuromuscular diseases LHON, which is an inherited 
predisposition to blindness. Homoplasmic point mutations in the region encoding 
subunit 1 of respiratory chain complex I (mitochondrially encoded NADH 
dehydrogenase 4 (MTND4, m.11778G>A)) were shown to be segregated with an 
inherited predisposition LHON in large maternal pedigrees; and in sporadic cases of 
a biochemically defined mitochondrial myopathy patients were found to have large 
heteroplasmic deletions of mtDNA [58].  Although the examples provided here 
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demonstrate a negative aspect of heteroplasmy, it is important to note that 
mitochondrial variants may provide a selective advantage in some settings so that 
heteroplasmy may be beneficial or detrimental depending upon the challenges faced 
by the organism. Due to the mtDNAs influence on longevity and multiple disease 
phenotypes, it is increasingly important to evaluate mtDNA in disease settings with 
unexplained causes or a wide range of phenotypes across effected patients that 
cannot be explained by Mendelian genetics.  
 
Figure 1.2 Mitochondrial DNA background 
A) Map showing migration and graphical location of mitochondrial haplogroups, Times listed 
in years before present. B) Depiction of mitochondrial DNA where each gene is color coded 
based on which ETC complex it belongs to. C) Depiction of the ETC with identical color 
coding as in panel B.   
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1.8 HIV-Associate Neurocognitive Decline 
 
HIV-1 infection is a complex clinical setting in which mitochondrial dysfunction 
appears to play a major role. Therapies for HIV-1 infection have altered the clinical 
course of disease such that infected individuals are now afflicted with a long-term 
chronic illness rather than an acute terminal disease. Concomitant with this shift in 
the disease’s natural history are changes in the demographics of the HIV-1-infected 
population. These changes manifest as an extended survival linked with the advent 
of combination antiretroviral therapies (cART) [69,70]. One result of the success of 
cART is that the HIV-1-infected population has shifted from a population below age 
45 years in 1996 to an HIV-1-infected population, with ~50% over 50 years of age in 
2015 [71]. While the lifespan of HIV-1-infected patients has increased, it has also 
become apparent that these individuals have an increased incidence of early-onset 
age-related neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s 
disease, and other dementia disorders [72]. The increased risk of neurocognitive 
decline may be due to the effect of HIV, the long-term side effects of cART 
therapies, or an interaction between both of these factors (Figure 1.3). 
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Figure 1.3 Working theory for HAND development 
Working theory depicting factors that are believed to contribute to the development of HIV-
associated neurocognitive decline. HIV infection itself can lead to inflammation and disease 
in the CNS. After the introduction of cART therapies the deleterious effects of HIV viral load 
are alleviated and patients are able to live a longer lifespan. With this increase in lifespan 
comes added stressors of normal aging, this in combination with the long-term side effect of 
cART drugs leads to the onset of HIV-associated neurocognitive decline. 
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Nucleoside reverse transcriptase inhibitors (NRTIs) are among the most 
commonly used drugs in cART cocktails to treat HIV-1 infection. These drugs are 
designed to be nucleoside analogs that inhibit the HIV reverse transcriptase by 
causing chain termination when incorporated in to the HIV viral genome during 
replication. Early generation NRTIs have been shown to display substantial 
disruption of the mitochondrial polymerase gamma [73]. Inhibition of this polymerase 
results in reduced mtDNA synthesis and mtDNA depletion, which are also known 
hallmarks of mitochondrial dysfunction during the normal aging process. The 
identification of this side effect lead to the development of new generation NRTIs 
with less affinity for the mitochondrial polymerases, but there is still cause for 
concern in regard to long term toxicity.  
Thus, despite the benefits of cART therapy, HIV-1-infected individuals often 
present with serious neuropsychological deficits [74,75]. For example, a significant 
co-morbidity associated with HIV-1 infection is HIV-1-associated neurocognitive 
disorder (HAND), a collective term used to denote the neurocognitive complications 
exhibited by HIV-1-infected individuals. Patients with HAND may present early signs 
of central nervous system (CNS) involvement such as psychomotor slowing, 
impaired encoding/ retrieval on declarative memory tests, and difficulties on 
executive tests including problems with prospective planning, mental control, and 
mental manipulation. Gait disturbances, falls, decreased manual dexterity, and 
neuropsychiatric problems including apathy or depression have also been described 
[76]. Past research suggests significant heterogeneity in the 
neuropsychological/neuropsychiatric impairment of people with HAND [77-79]. 
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Although the biological basis for this heterogeneity is not clear, it is likely that an 
individual’s genetic makeup contributes to these differences. 
 Classically, genetic variation has been associated with the nuclear genome. 
However as discussed earlier, a significant amount of genetic variation also occurs 
in the mitochondrial genome as discussed earlier. This could be a potential 
component that is contributing to the heterogeneity we see in the neurocognitive 
status of these HIV patients. Importantly for the present study, neural complications 
of HIV/cART such as peripheral neuropathy have already been shown to be more 
prevalent in patients with the mitochondrial haplogroup L0a2 while patients with 
haplogroup L2a have a reduced risk for peripheral neuropathy [80]. Other examples 
include the findings that haplogroups J and UK are underrepresented in Parkinson’s 
disease populations, suggesting some protection from the disorder, and that 
haplogroup T is underrepresented in Alzheimer’s patients [81,82]. Thus, 
accumulating evidence suggests that mitochondrial DNA variation alters an 
individual’s susceptibility to disease and supports the possibility that mitochondrial 
variation could play a role in the differential susceptibility of HIV-1 patients to HIV-
associated co-morbidities. 
 
1.9 Aims Statement 
 
 This thesis work aims to evaluate mitochondria’s role in premature aging as it 
relates to HIV-associated neurocognitive decline and to identify potential adjuvant 
therapies for premature aging and NRTI toxicity. Aim 1 sets out to correlate 
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mitochondrial DNA variation with heterogeneity in the severity of HAND in order to 
develop mtDNA variation as a susceptibility marker (Chapter 2). Aim 2 delves into 
understanding the potential side effects of NRTI drugs and how they may be 
affecting both mitochondria and senescence. Additionally aim 2 incorporates 2 
promising therapeutic regimens to combat these negative side affects (Chapter 3). 
Aim 3 begins to break down the global transcriptional benefits of therapeutic 
regimens to provide insight into mechanism of action (Chapter 4). Taken together 
these aims highlight the important role for mitochondria in premature aging settings 
and define two potential therapeutics that may help combat clinical signs of 
premature aging.  
 
CHAPTER 2: MITOCHONDRIAL GENETIC INFLUENCE ON HIV-ASSOCIATED 
NEUROCOGNITIVE DECLINE  
 
2.1 ABSTRACT 
 
Evolutionary divergence of the mitochondrial genome has given rise to 
distinct haplogroups. These haplogroups have arisen in specific geographical 
locations and are responsible for subtle functional changes in the mitochondria that 
may provide an evolutionary advantage in a given environment. Based on these 
functional differences, haplogroups could define disease susceptibility in chronic 
settings. In this study, we undertook a detailed neuropsychological analysis of a 
cohort of long-term HIV-1-infected individuals in conjunction with sequencing of their 
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mitochondrial genomes. Stepwise regression analysis showed that the best model 
for predicting both working memory and declarative memory were age and years 
since diagnosis. In contrast, years since diagnosis and sub-haplogroup were 
significantly predictive of psychomotor speed. Consistent with this, patients with 
haplogroup L3e obtained better scores on psychomotor speed and dexterity tasks 
when compared to the remainder of the cohort, suggesting that this haplogroup 
provides a protective advantage when faced with the combined stress of HIV-1 
infection and long-term antiretroviral therapies. Differential performance on 
declarative memory tasks was noted for individuals with other sub-L haplogroups, 
but these differences were not as robust as the association between L3e and 
psychomotor speed and dexterity tasks. This work provides evidence that 
mitochondrial haplogroup is related to neuropsychological test performance among 
patients in chronic disease settings such as HIV-1 infection.  
 
2.2 INTRODUCTION  
 
Recent research has begun to analyze the impact of mitochondrial genetics 
on HIV-associated neurologic co-morbidities. For example, the relationship between 
mitochondrial haplogroup and sensory-neuropathy has been examined in patients 
from the CNS HIV AntiRetroviral Therapy Effects Research (CHARTER) study. 
These data suggests that single nucleotide polymorphisms (SNPs) associated with 
haplogroup L1c and J may be associated with a decreased prevalence of this co-
morbidity [80]. More recently the same research group released results showing that 
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in a cohort of Hispanic individuals, the typical Native-American haplogroup B 
exhibited lower global deficit scores (indicating better neurocognitive performance), 
suggesting an influence of mitochondria on neuropsychological functioning [83].  
In order to further examine the potential relationship(s) between mitochondrial 
variation and HAND, a team of trained neuropsychologists performed a detailed 
neuropsychological evaluation assessing psychomotor speed and dexterity 
functioning, declarative memory, and executive control/working memory in a 
subgroup of the Drexel Medicine CNS AIDS Research and Eradication Study 
(CARES) cohort, as well as a complete sequence analysis of their mitochondrial 
genomes. The Drexel Medicine CARES cohort is a continually expanding cohort of 
557 patients, which spans approximately 2,179 longitudinal visits. This analysis 
allowed me to identify genetic variation in the mtDNA that may be associated with 
these neurocognitive functions. These results will further evaluate the hypothesis 
that for patients with chronic HIV-1 infection, specific mitochondrial haplogroups may 
be associated with specific patterns of neuropsychological strengths and 
weaknesses.  
 
2.3 RESULTS 
 
2.3A Demographic and Clinical Characterization of Haplogroups 
In order to evaluate the main hypothesis that mitochondrial variation can 
affect HAND phenotypes, I first compiled and analyzed our neurocognitive data with 
respect to haplogroup for the set of 157 patients. Demographics of the patient 
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population are presented in Table 2.1. There were no significant differences in HIV-
related parameters by haplogroup (CD4 counts, years on therapy, viral load), and 
the majority of patients in all haplogroups reported African American ancestry 
(96.1% of L haplogroup and 75.9% of non-L).  
 
2.3B Reduction of Neuropsychological Data and Neuropsychological 
Characterization of the Groups 
The Spanish and English Neuropsychological Assessment Scales (SENAS) 
neuropsychological protocol described below in the methods was selected, in part, 
because of the availability of normative data stratified by age, education, population 
group, and sex [84,85].  Demographically adjusted T-scores for the nine 
neuropsychological parameters were reduced to three neurocognitive composites 
based on the results of a principal component analysis (PCA) with varimax rotation 
preformed with the help of trained neuropsychologists Dr. Libon and Dr. Giovannetti 
(Figure 2.1A). These 3 composites accounted for 69.15 percent of variance (Figure 
2.1B). As displayed in Figure 2.1B Psychomotor Speed and Dexterity (Pegboard, 
Trails A, Trails B) accounted for 22.11% of the variance. Executive Function/Working 
Memory measures (letter fluency, semantic fluency, SENAS Working Memory Index) 
accounted for 21.33% of the variance. Finally, Declarative Memory measures 
(BVMT and SENAS Verbal Word List Learning) accounted for 25.71% of the 
variance (Figure 2.1A and B). Based on the results of this PCA, the nine SENAS 
neuropsychological variables were reduced to three composite indices by averaging 
the T-scores tests within each factor (psychomotor speed and dexterity composite= 
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43.30 + 7.59; declarative memory composite= 40.00 + 10.93; executive 
function/working memory composite= 47.13 + 8.31) (Table 2.1). Histograms showing 
the normal distribution of each composite score are shown in Figure 2.1C.
  
Figure 2.1 Principle component analysis identifies functional groups among 
neurocognitive tests. 
A) Rotated component matrix of norm-derived neuropsychological test scores used to 
determine neuropsychological composite scores. Component 1 = declarative memory; 
component 2 = motor; component 3 = working memory. Red boxes show groupings for each 
component determined by the PCA. B) The nine neurocognitive evaluation scores were 
compiled in SPSS. Total variance explained by each component is contained under the 3 
columns listed under Initial Eigenvalues. Components identified as explaining the maximum 
amount of variance in the data are listed under Extraction Sums of Squared Loadings. Total 
amount of variance in the model explained by each of these 3 components after varimax 
rotation is listed under Rotation Sum of Squared Loadings. Total variance explained by the 
PCA and variance explained by each component of the PCA is outlined in red boxes. C) 
Histograms showing that the three composite scores were normally distributed. 
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Mean neuropsychological composite scores shown in Table 2.1 demonstrate 
that overall the cohort/sub cohorts performed within the average (i.e., T-scores 
between 57 and 43) and below average (i.e., T-scores between 42 and 36) range on 
the three neuropsychological composite scores. This verifies that we are indeed 
working with a neurocognitively declined cohort as compared to the average scores 
of uninfected individuals. Also, there was no significant difference between the 
groups on the three neuropsychological composites.  
 
 
 Overall  
(N = 157)  
L Haplogroup 
(N=128)  
Non-L 
Haplogroups 
(N=29)  
L3e Sub-
Haplogroup 
(N=29)  
Non-L3e 
Sub-
Haplogroups 
(N=128)  
Mean Age 
(range)  
51.85 (27-73)  51.79 (27-73)  52.14 (27-70)  51.52 (33-
73)  
51.92 (27-71)  
Female  50 (33.1%)  44 (34.4%)  9 (31.0%)  14 (48.3%)  39 (29.8%)  
African 
Ancestry  
145 (92.4%)  123 (96.1%)  22 (75.9%)  27 (93.1%)  118 (92.2%) 
Initial Mean 
CD4 (cells/uL) 
(SD)  
379.26 
(298.66)  
371.22 
(294.02)  
415.03 
(321.45)  
332.29 
(276.05)  
389.38 
(303.36)  
Nadir Mean 
CD4 (cells/uL) 
(SD)  
230.78 
(206.25)  
224.97 
(209.58)  
256.62 
(193.22)  
186.71 
(219.08)  
240.27 
(203.26)  
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Latest Mean 
CD4 (cells/uL) 
(SD)  
673.48 
(364.34)  
665.34 
(384.24)  
709.69 
(260.22)  
618.68 
(338.02)  
685.28 
(369.93)  
Initial Viral 
Load 
(copies/mL) 
(SD)  
104731.61 
(420372)  
118147.58 
(464637)  
42922.29 
(76765)  
260597.68 
(887576)  
70900.21 
(206704)  
Peak Viral 
Load 
(copies/mL) 
(SD)  
256900.99 
(744920)  
240389.98 
(548195)  
332969.54 
(1331970)  
579099.79 
(1014128)  
186966.36 
(657050)  
Latest Viral 
Load 
(copies/mL) 
(SD)  
5010.03 
(45887.3)  
6063.33 
(50595)  
157.32 
(510.76)  
22981.64 
(107491)  
1109.21 
(6557)  
Mean Years 
on HAART 
(SD)  
12.12 (7.66)  11.70 (7.57)  14.00 (7.96)  10.10 (7.63)  12.56 (7.64)  
Mean Years 
Since 
Diagnosis (SD)  
18.79 (7.72)  18.49 (7.75)  20.17 (7.53)  16.45 (7.77)  19.31 (7.64)  
Mean motor 
score (SD)  
43.30 (7.59)  43.18 (7.56)  43.88 (7.84)  47.41 (7.37)  42.46 (7.38)  
Mean working 
memory score 
47.13 (8.31)  47.03 (8.37)  47.55 (8.19)  46.52 (6.74)  47.27 (8.65)  
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(SD)  
Mean 
declarative 
memory score 
(SD)  
40.00 (10.93)  39.38 (10.74)  42.81 (11.5)  40.90 (9.40)  39.81 (11.26)  
Table 2.1: Drexel Medicine CARES cohort descriptive data for overall cohort, L 
haplogroups, non-L haplogroups, L3e haplogroups and non-L3e haplogroups. 
 
2.3C Haplogroup Principal Component Analysis  
In order to evaluate the influence of haplogroup on neurocognition, the three 
PCA- derived neuropsychological composite scores were analyzed in conjunction 
with mitochondrial haplogroup. Using the R package SNPRelate, we performed a 
PCA on the mitochondrial genomic data. Haplogroup information assigned using 
Haplofind [86] was then used as an input to color code individual patient samples 
(Figure 2.2 A). This mitochondrial genomic PCA identified 3 distinct genetic groups 
in our cohort; L0, L1 and a combined group of L2+L3+Non-Ls (Figure 2.2 B-D). 
These groups are consistent with the ancient origin of the L0 and L1 haplogroups 
relative to the L2 and L3 split at ~80-60 ka [87-89]. Subsequent analyses of the 
differences in neurocognitive scores between the three major haplogroups revealed 
no significant differences (Kruskal-Wallis testing: psychomotor speed and dexterity 
p-value = 0.67, declarative memory p-value = 0.71, executive function/working 
memory p-value = 0.58) (Figure 2.2E). Further analysis, testing the difference in 
neurocognitive scores between the major L groupings, L0, L1, L2, L3 and non-L 
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haplogroups showed no statistically significant difference between groups (Kruskal-
Wallis testing: psychomotor speed and dexterity p-value = 0.31, declarative memory 
p-value = 0.45, executive function/working memory p-value = 0.75) (Figure 2.3 A-D).  
 
Figure 2.2 Principle component analysis on patient genotype information. 
A) Principle component analysis revealed 3 genotype groupings. Color-coding showed 
patients clustering in 3 major groups L0, L1 and all other haplogroups. Performed using 
SNPRelate R package B-D) Box whisker plot grouping haplogroups as follows L0 vs L1 vs 
L2+L3+NL vs. the 3 complied neuropsychological composite scores. Red dotted lines 
indicate mean T-scores. E) Statistical analysis between the 3 groups was performed using 
SPSS and Kruskal-Wallis testing (p<0.05). 
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Figure 2.3 Major haplogroups show no association with neurocognitive performance. 
A-C) Box whisker plots of the haplogroups against the three compiled neuropsychological 
composite scores: A- Psychomotor speed B- Working memory C-Declarative memory. Red 
dotted lines indicate average T-scores. D) SPSS table reporting p-values for Kruskal-Wallis 
testing. 
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2.3D Sub-Haplogroup Analysis 
Because we observed no difference in the major L vs non-L haplogroups, we 
further defined sub-L haplogroups that dominated the patient cohort to examine 
potential patterns associations with neuropsychological performance on a finer level. 
The initial analysis examined differences between the major sub-L haplogroups 
present in the cohort (L0a, L1b, L1c, L2a, L2b, L2c, L2d, L2e, L3b, L3d, L3e, L3f and 
all non-L haplogroups) (Figure 2.4 A-C).  This analysis revealed no statistical 
differences in neurocognitive function overall (Kruskal-Wallis testing: psychomotor 
speed and dexterity p-value = 0.51, declarative memory p-value = 0.26, executive 
function/working memory p-value = 0.25) (Figure 2.4 D). However, an analysis 
separating the sub-L haplogroups as comparators to the remainder of the cohort 
revealed two sub-L haplogroups that did significantly differ from the rest of the 
cohort. Table 2.2 shows p-values for all comparisons and the number of patients in 
each sub-group; no values are shown for sub-haplogroups that represent less than 
5% of the cohort. 
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Figure 2.4 Sub-haplogroups show no association with neurocognitive performance 
when compared to one another. 
A-C) Box whisker plots of the sub-haplogroups against the three compiled neuroscores: A- 
Psychomotor speed B- Working memory C-Declarative memory. Red dotted lines indicate 
the mean T-scores. D) SPSS table reporting p-values for Kruskal-Wallis testing. 
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Sub-L-
Haplogroup  
Number of 
people  
Motor 
Function     
p-value  
Working 
Memory         
p-value  
Declarative 
Memory       
p-value  
GDS  
L0a  6  --  --  --  --  
L1b  15  0.306  0.177  0.205          0.842  
L1c  11  0.909  0.980  0.240      0.735  
L2a  26  0.100  0.025  0.259  0.022  
L2b  3  -- --  --  --  
L2c  5  --  --  --  --  
L2d 2  --  --  --  --  
L2e  2  --  --  --  --  
L3b  8  0.704  0.713  0.354  0.899  
L3d  12  0.811  0.063  0.060  0.203  
L3e  24  0.004  0.650  0.629  0.218  
L3f  7  --  --  --  --  
NL  28  0.774  0.847  0.168  0.343  
Table 2.2: Sub-haplogroup associations with neurocognitive performance when 
segregated from the cohort as a whole. 
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Individuals of L2a had a lower executive/working memory composite score 
than the rest of the cohort (p=0.025) (Figure 2.5 A). Additionally, individuals of L3e 
haplogroups had a higher psychomotor speed and dexterity composite score than 
the rest of the cohort (p= 0.004; Figure 2.5 B). Multiple testing correction using 
Benjamini-Hochberg methods indicated that the association between L3e and 
psychomotor speed and dexterity maintained significance, while the relationship 
between L2a and the executive/working memory composite was not as robust and 
fell below our p <0.05 cut off for statistical significance.  
Figure 2.5 Sub-haplogroups L2a and L3e show statistically significant association 
with neurocognitive performance when segregated from the cohort as a whole. 
A-B) Box whisker plots of 2 sub-haplogroups (L2a and L3e) significantly associated with 
performance on at least one neuropsychological composite score with respect to the rest of 
the cohort. Working memory (A) and psychomotor speed and dexterity (B.) Mann-Whitney U 
statistical testing (p-value <0.05). Red dotted lines indicate mean values expressed as T-
scores.  
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 Because the global deficit score (GDS) is a commonly used tool to assess 
neurocognitive function, we also examined differences in GDS between the major 
sub-L haplogroups with at least a 5% present in the cohort; L1b, L1c, L2a, L3b, L3d, 
L3e and all non-L haplogroups collectively.  Results of this analysis showed that 
there was no difference in GDS between sub-haplogroups (Kruskal-Wallis p-value = 
0.572; Data not shown). When each sub-haplogroup was tested separately as a 
comparator to the rest of the cohort, there was only a difference in GDS when 
comparing L2a to all non-L2a individuals (p-value = 0.022), although this association 
did not remain significant after Benjamini-Hochberg correction (Data not shown). 
 
2.3E Regression Analysis 
To understand and validate the trends in our data, we performed three 
stepwise linear regressions for each composite score to determine which factors in 
our cohort best predict neurocognition. In these analyses each composite score was 
the dependent variable for 3 separate regression models. Independent variables 
were age, gender, years since therapy started, years since diagnosis, and sub-
haplogroup. Sub-haplogroups that represent at least 5% of individuals in the cohort 
were input as seven separate binary variables L1b, L1c, L2a, L3b, L3d, L3e, and 
Non-Ls (e.g. 1 meaning the patient is Llb and 0 meaning the patient is not L1b). The 
best individual predictor for executive/working memory was haplogroup L2a 
(explaining roughly 5.7% of the variation) and the best overall model also included 
age and years since diagnosis (explaining roughly 13.1% of the variation) (Table 
2.3). The best individual predictor for declarative memory was age (explaining 
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roughly 3.7% of the variation) and the best overall model also included years since 
diagnosis (explaining roughly 8.6% of the variation) (Table 2.3). In contrast, the best 
individual predictor and overall model for psychomotor speed and dexterity only 
included haplogroup L3e (explaining roughly 6.1% of the variation) (Table 2.3). 
These results are consistent with the literature evidence that age and years since 
diagnosis affecting neurocognitive performance [69,90] and suggests different sub-
haplogroups confer differential sensitivity to motor components of HAND.  
Additionally, variation in GDS was evaluated using the same step-wise regression 
parameters and seems to trend similarly to executive/working memory with L2a, 
age, and years since diagnosis, being the best predictors (Data not shown).  
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 Cognitive Components (Dependent Variables)  
 Motor Function  Working 
Memory  
Declarative 
Memory  
Best individual Predictor  HapL3e  HapL2a  Age  
Best overall Model HapL3e  HapL2a, Age, 
YrSdiag  
Age, YrSdiag  
R Squared (Predictor)  0.061  0.057  0.037  
R Squared (Model)  0.061  0.131  0.086  
F value (Predictor)  9.343  8.843  5.693  
F value (Model) 9.343  7.334  6.870  
Sig. (Predictor)  0.003  0.003  0.018  
Sig. (Model)  0.003  HapL2a: 0.005, 
Age: 0.001, 
YrSdiag: 0.030 
Age: 0.002, 
YrSdiag: 0.006  
Beta (Predictor)  -0.247  0.239  0.193  
Beta (Model)  -0.247 HapL2a: 0.221, 
Age: 0.261, 
YrSdiag: 0.175  
Age: 0.253, 
YrSdiag: -0.229 
Table 2.3: SPSS output information from stepwise linear regression. 
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2.3F Further L3e Analysis 
Due to the associations found between individuals of L3e sub-haplogroups 
and psychomotor speed, we next tested whether there were specific SNPs 
associated with psychomotor and dexterity performance (Figure 2.6). In order to 
determine which variants were overrepresented in L3e individuals we used a 
Fisher’s exact testing method and filtered for variants that were significantly 
overrepresented in patients of the L3e haplogroups compared to non-L3e patients. 
Of the variant positions that are over-represented in the L3e sub-haplogroups of our 
cohort, positions 150, 10819, 14212 and 14905 were also positively correlated with 
the psychomotor speed and dexterity composite score (Figure 2.6 A). The 150 
variant is particularly interesting due to the fact that it lies in the control region of the 
mtDNA, which is a region of the mitochondrial genome critical for both transcription 
and DNA synthesis. Although variants in this region are highly recurrent in multiple 
haplogroups, they have been shown to correlate with a variety of phenotypes [91] 
and in our cohort individuals who have the C150T variant have significantly higher 
motor scores (p=0.045) (Figure 2.6 B). The other variants over-represented in the 
L3e subgroups correlated with the psychomotor speed and dexterity composite 
score were synonymous changes relative to the rCRS mitochondrial reference, 
presumably having little effect on the physiological function of the protein, although 
an impact on mRNA stability or translation efficiency are possible.  
 
2.3G Analysis of Specific Psychomotor Tasks  
To better understand the association between the L3e haplogroup and 
psychomotor speed and dexterity, we analyzed each of the three individual variables 
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that comprised this score and looked for differences between L3e and non-L3e 
individuals. This found no significant difference in performance on the Trail Making 
Test- Part B, a test that assesses the capacity to maintain complex mental set (p-
value = 0.373; Figure 2.6 C). By contrast, significant differences between L3e and 
non-L3e were seen in time to completion from both the Grooved Pegboard and Trail 
Making Test- Part A, tests that assess dexterity and psychomotor speed (p-
values=0,021 and 0,011 respectively; Figure 2.6 C).  
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Figure 2.6 Variants overrepresented in the L3e sub-haplogroup showing association 
with psychomotor speed and dexterity. 
A) Fisher’s exact test was used to determine the top 10 variants that were overrepresented 
in the L3e sub-haplogroup (Fishers exact: p-value < 0.001). Table shows variant, the gene 
containing the variant, S- synonymous amino acid change vs NS- non-synonymous amino 
acid change and percent of individuals in L3e or non-L3e who possess each variant. B) Dot 
plot showing individuals motor score with or without the variant at position 150 (./. reference 
base in RCRS). Red dotted line indicates mean values of the SENAS control population for 
the T-scores. C) Individual test scores, which, comprise the PCA derived motor score, were 
individually evaluated between L3e and non-L3e individuals. Red box indicates simple motor 
scores, Green box represents complex motor score. 
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2.3H Association of All Variants 
Due to the fact that individual variants were associated with differences in 
neurocognition, I set out to correlate all individual variants with the three 
neurocognitive-scores. I first determined which positions in our variant table were 
perfectly correlated with one another, that is to say when there is a variant at one 
position, there was always a variant at another position. This reduced the number of 
distinguishable genotypes from 980 to 659. Using logistic regression with the 659 
positions and the three neuropsychological composite scores, no significant 
positions survived Benjimini-Hochberg MTC, although there were several interesting 
trends (Data not shown). Additionally, heteroplasmy across the mitochondrial DNA 
was evaluated and the number of heteroplasmic sites per patient were calculated 
but these values did not seem to correlate with neurocognitive score (Data not 
shown). 
 
2.3I Analysis of Associations Between Neurocognitive Function and 
Sub-haplogroups Excluding Non-L Subjects. 
Racial differences may confound associations between phenotype data and 
mitochondrial haplogroups. However, the majority of non-L patients in our cohort 
indicated an African American ancestry, suggesting that their racial backgrounds 
were similar to the L patients. Nonetheless, I performed an analysis of the data using 
only patients within the L haplogroup to determine whether the associations 
identified in the entire cohort would also be detected among subjects with an L 
haplogroup. This analysis revealed the same associations between L2a and L3e and 
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executive function/working memory and psychomotor speed and dexterity as 
identified in the larger cohort, although in this case the association between L3e and 
psychomotor speed and dexterity was not significant following correction for multiple 
comparisons (Data not shown). 
 
2.4 DISCUSSION 
 
Mitochondrial haplogroups are thought to represent functionally distinct 
evolutionarily selected populations. Multiple studies have demonstrated a complex 
interaction between the mitochondrial genome and disease progression, suggesting 
that mitochondrial genetics can alter disease course [81,92]. The results of our PCA 
analysis were consistent with the known evolutionary divergence of the L 
haplogroups. For example, L0 patient samples, which represent the oldest 
mitochondrial haplogroup arising ~128.2ka [87,89,93], grouped separately in the 
PCA analysis from the remainder of the patient sample. Similarly, the L1 samples, 
that represent the next group to diverge in evolutionary terms at ~123.8 ka [89,94], 
grouped separately as well. The remainder of the patient samples which included 
L2, L3, and the non-L patient samples, grouped together in this analysis. The L3 
lineage is thought to have arisen in the eastern African mitochondrial gene pool 
approximately 60-70 ka and subsequently diverged into multiple sub-clades 
including the N and M lineages, which gave rise to all non-L haplogroups outside of 
Africa. The L3e lineage arose in central African (Sudan region) 35-60 ka and has 
further diverged into a number of sub-clades L3e1’2’3’4 which have spread across 
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sub-Saharan Africa and now constitute roughly one third of all L3 lineages (refer 
back to Figure 1.2A)[87-89,94].  
Persons infected with HIV-1 often present with motor disabilities including 
performance on tests that assess discrete fine motor operations [95] and there 
appears to be involvement of the basal ganglia-thalamo-cortico networks [96]. 
Valcour et al., assessed motor impairment in HIV-1 infection using the Unified 
Parkinson’s Disease Rating Scale (UPDRS) and found that HIV-1-infected patients 
presented with bradykinesia, tremor, and reduced distal muscle agility [97]. These 
results are consistent with the data reported in the current research in that the 
relationship between the L3e haplogroups and motor tests was confined to tests that 
required either fine motor agility (e.g., the Pegboard Test) or motor speed (Trail 
Making- Part A).  The Trail Making Test- Part B differs from our other motor tests in 
that Trails B provides a measure of the executive ability to maintain a complex 
mental set.  The observation that L3e haplogroups dissociates between simple 
(Pegboard/ Trails A) versus complex (Trails B) suggests some specificity regarding 
this haplogroup and simple motor operation.  Further research is necessary to 
explore these relationships.   
Within the L3e haplogroups, we identified variants that show promising trends 
with neurocognition and have also been previously reported in the literature. One 
such variant is the 150 position, which is of particular interest due to its enrichment 
in centenarians of European descent [98]. Centenarians are individuals who live to 
great age evading the onset of normal age-related pathologies, suggesting the 
presence of inherent longevity assurance mechanisms. The 150 position is a 
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recurrent change, which has arisen in several different haplogroups during the 
evolution of the mitochondrial genome, suggesting that this site may be unstable. 
However, cybrid analysis utilizing the C150T variant in either a U or J haplogroup 
background suggested that the C150T produces lower levels of cellular ROS [99]. 
Lower ROS production in response to either HIV-1 infection or nucleoside reverse 
transcriptase inhibitor (NRTI) treatment may have long-term consequences in terms 
of aging and senescence. In the laboratory, we have examined the impact of 
exposure to NRTIs, which are a component of current cART therapy, in human cells 
and find a significant increase in both mitochondrial and cellular ROS in cells treated 
with NRTIs leading to activation of unique mitochondrial stress responses and 
activation of the senescence program, this data is discussed in full in chapter 3 
[100]. These results suggest that increased levels of mitochondrial ROS in a chronic 
setting may activate senescence, which is a component of neurodegenerative 
disorders such as Alzheimer's disease and other neurocognitive impairments [101]. 
Another L3e variant that is particularly interesting is the T2352C variant. This 
variant lies in the 16S rRNA gene, which is important for mitochondrial protein 
synthesis, as it is a critical subunit of mitochondrial specific ribosomes. A variant in 
this gene may alter ribosomal structure, which may provide a potential benefit to L3e 
individuals. More interestingly, a subset of the 16S rRNA region of the mitochondrial 
genome is also thought to code for a small 24 amino acid peptide called humanin. 
This peptide is quite controversial since scientist have not fully elucidated whether it 
is specifically derived as a nuclear gene product or a mitochondrial gene product. 
Intriguingly, about 755 nuclear insertions of mitochondrial origin have been identified 
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with relatively high homology and could explain the discrepancies in the field in 
regards to humanin origin [102]. Nuclear insertions of mitochondrial origin that reflect 
humanin sequences are found on chromosomes 1-13 with varying degrees of 
homology though none of the deduced peptide sequences are identical to that found 
in the original screen. Humanin was first discovered in a screen for cDNA from 
Alzheimer’s disease patient brain tissue where multiple sequences were identified to 
be identical to the 16S rRNA mitochondrial sequence [102]. Since this screen this 
peptide has shown both cyto-protective and neuro-protective properties [103]. The 
T2352C variant lies upstream of the postulated coding region for this peptide but 
may affect the manner in which it is expressed. Again, this evidence may suggest a 
role for the T2352C variant as a protective variant in the L3e patient population 
either through altering 16S rRNA activity or humanin production. 
A limitation of this study is the small size of the cohort, which limited our 
power to detect associations between haplogroup with neurocognitive function such 
as working memory.  Similarly, the cross-sectional design of the study presents 
limitations, however future longitudinal assessment of neurocognition in this cohort 
will allow a more detailed analysis of the influence of mitochondrial genetic variation 
in regards to HAND progression. Despite the limitations, the data suggests that there 
is an association between motor function and the presence of sub-haplogroup L3e in 
the cohort. 
A recently completed analysis of haplogroup association with HAND in the 
CHARTER cohort identified Native American haplogroup B as protective within the 
admixed Hispanic haplogroups although patients carrying the haplogroups 
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demonstrated lower performance overall [83]. Although the CHARTER study 
contains a relatively large percent of African American patients, no sub-haplogroup 
analysis has been carried out specifically examining potential associations with 
motor function. Future work will reveal if the associations identified in our study can 
be verified in other cohorts. Further analysis for this study includes analyzing trends 
associated with the occurrence of insertions or deletions, determining if the degree 
of heteroplasmy present in these individuals effects neurocognition and analysis of 
nuclear genes with mitochondrial functions. Together this study will further 
characterize the role mitochondria may play in the progression of HAND. 
The idea that mtDNA variation can have profound effects on age related co-
morbidities, like in the case of HAND, could be an important aspect to consider when 
developing therapies to treat said diseases. As previously stated, NRTI drugs have 
been shown to inhibit the mt-POLG but not much more is known about how these 
drugs could be affecting mitochondrial/cellular function. More studies need to be 
done in order to dissect how NRTI drugs affect cells in-vitro. The next chapter will 
help to reveal more insight into why and how NRTI drugs are toxic and in addition 
open up an evaluation of potential therapeutic options for patients suffering from 
these negative side effects. 
 
CHAPTER 3: MITOCHONDRIAL DYSFUNCTION INDUCED SENESCENCE IN-
VITRO IS TRIGGERED BY NRTIS 
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3.1 ABSTRACT 
 
Although it is known that NRTI drugs affect the mitochondria, the intracellular 
mechanisms by which this stress is communicated to the nucleus and impacts cell 
fate decisions are not well defined. In this study, we report that NRTI drugs, 
commonly used in antiretroviral therapies, and known to induce mitochondrial 
dysfunction, activate mTORC1 signaling triggered by mitochondrial-generated 
reactive oxygen species (ROS) results in activation of the senescence program.  We 
show that exposure of human cardiac fibroblasts to NRTIs, increases mitochondrial 
ROS and leads to a rise in intracellular ROS concomitant with activation of 
mTORC1. In this setting, it appears that mTORC1 activates senescence through 
facilitating a p53-mediated response. Inhibition of mTORC1 by rapamycin or 
methionine restriction blocks activation of the senescence program in human cells. 
Decreasing mitochondrial ROS directly also blocks mTORC1 activity and prevents 
the onset of senescence. Consistent with these results, mitochondrial-specific ROS 
increased in cells undergoing replicative senescence along with ribosomal p70 
phosphorylation, revealing a novel link between mitochondrial dysfunction, mTORC1 
signaling, and the senescence program.  
 
3.2 INTRODUCTION  
 
Mitochondria are the principle cellular organelles responsible for ATP 
production, calcium regulation, biosynthetic processes, and apoptotic regulation. 
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They are also a major source of free radicals, with potential to generate reactive 
oxygen species (ROS) within the cell [104]. Biosynthetic and ATP-producing 
activities within the mitochondria are dependent upon both nuclear and 
mitochondrial-encoded proteins, and a dynamic communication exists between the 
mitochondria and nuclear genomes which has not yet been fully elucidated.  
The target of rapamycin or TOR complex (known as mTOR in mammals) is a 
focal point for the integration of nutrient availability, growth factor signaling, and 
stress responses [105-108]. The mTORC1 complex has been localized to several 
intracellular organelles including the lysosome, endoplasmic reticulum, nucleus, and 
mitochondria [112-115]. At present, the functional significance of mitochondrial 
localization of mTOR is not well defined. 
In the current study, we utilized the nucleoside analogs tenofovir disoproxil 
fumarate (TDF) and emtricitabine (FTC) to examine the hypothesis that 
mitochondrial stress signaling induces senescence using a cell model system. 
These compounds (referred to as NRTIs for simplicity), are commonly used in 
combination as an antiretroviral cocktail, and competitively inhibit HIV reverse 
transcriptase but also inhibit mitochondrial DNA polymerase γ, leading to 
mitochondrial dysfunction [109,110]. As a consequence, individuals receiving NRTIs 
as a component of highly active antiretroviral therapy for HIV-1 infection [69,111] are 
at increased risk for developing aging-associated comorbidities. The underlying 
mechanisms for these co-morbities are not clear but mitochondrial dysfunction is 
suspected to be involved. Although the current generation of NRTIs exhibit a lower 
affinity for mitochondrial DNA polymerase γ compared with earlier NRTIs, 
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mitochondrial toxicity remains a significant concern [112,113]. In Aim 1 we examined 
neurocognition as one of the co-morbidities associated with this toxicity but another 
very common comorbidity is cardiovascular disease which is also heavily linked to 
mitochondrial dysfunction [114]. For this reason, in addition to their well studied 
ability to undergo senescence, we chose to use human cardiac fibroblasts to 
evaluate the question of NRTI toxicity. 
We find that NRTI exposure impairs cellular homeostasis through 
mitochondrial dysfunction and oxidative stress, causing aberrant activation of 
p70S6K via mTORC1 and ultimately leading to premature senescence. These 
effects were significantly reduced in cells treated with rapamycin, methionine 
restriction or a mitochondrial-ROS scavenger, such as mito-Q. This study identifies a 
novel mechanism linking mitochondrial dysfunction and the activation of mTORC1 
with cellular senescence. 
 
3.3 RESULTS  
 
3.3A Mitochondrial effects of nucleoside/nucleotide analogs and 
protection by rapamycin and methionine restriction 
We examined the effects of combination treatment with TDF and FTC 
(referred to as NRTIs for simplicity) on mitochondria in human cardiac fibroblasts. 
Exposure to NRTIs for 7 days produced a significant increase in both mitochondrial 
membrane potential and mitochondrial ROS (Figure 3.1, A-B). Cultures grown in the 
presence of rapamycin or methionine restriction (3mg/L and 1mg/L) exhibited a 
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lower level of increase in mitochondrial membrane potential or mitochondrial ROS 
following exposure to NRTIs compared to control cultures (30 mg/L) (see 
comparisons in Figure 3.1, A-D; grey, red and black bars). 
 
 
Figure 3.1 Mitochondrial alterations due to NRTI treatment plus amelioration with 
interventions 
Changes in mitochondrial parameters in response to NRTIs, rapamycin and methionine 
restriction. Human cardiac fibroblasts were maintained with or without rapamycin (1 nM) or 
methionine restriction (3mg/L or 1mg/L). Following 7 days’ exposure to NRTIs, parameters 
of mitochondrial status and function were examined. blue bars represent cells maintained 
under standard culture conditions, grey bars represent 3mg/L methionine restriction, red 
bars represent 1mg/L methionine restriction and black bars represent cells maintained in the 
presence of rapamycin. Panels A and B contain bar graphs of triplicate measurements for 
mitochondrial ROS (Panel A) and membrane potential (Panel B). * shows significance 
between a culture setting with and without NRTIs (20ug/ml). # shows significance from NRTI 
treatment with or without an intervention p<0.05.  
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An indirect assessment of mitochondrial activity was performed using a 
Seahorse Bioanalyzer in cultures maintained under standard culture conditions or in 
the presence of rapamycin or methionine restriction. Calculated rates of basal 
respiration, maximal respiration, and proton leak increased significantly when human 
cardiac fibroblasts were exposed to NRTIs while ATP-linked respiration decreased 
significantly (Figure 3.2, A-D). Rapamycin treated cells in the presence of NRTIs 
showed lower basal respiration, maximal respiration and proton leak and had no 
significant change in ATP-linked respiration compared to NRTI treatment alone 
(Figure 3.2 A-D, red bar). Methionine restricted cells at 3mg/L treated with NRTIs 
showed an increase in both basal and maximal respiration but at a level significantly 
lower than with NRTIs alone. These cells also displayed an increase in ATP-linked 
respiration and no change in proton leak in the presence of the NRTIs. Methionine 
restricted cells at 1mg/L treated with NRTIs showed a decrease in all four ETC 
readouts (Figure 3.2 A-D). 
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Figure 3.2 NRTI effects on ETC plus amelioration with interventions 
Calculated rates of basal respiration are presented in Panel A, ATP-linked respiration in 
Panel B, proton leak in Panel C and maximal respiration in Panel D. Each Seahorse 
experiment represents a minimum of three independent experiments with similar results. * 
shows significance between a culture setting with and without NRTIs. 30mg/L is the control 
setting where the standard methionine in the media is 30mg/L. NRTI treatments were done 
at 20ug/ml for 7 days. Interventions shown are 1 and 3mg/L methionine restriction and 1nM 
rapamycin. # shows significance from NRTI treatment with or without an intervention p<0.05. 
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 The effect of NRTI exposure on steady state levels of a subset of ETC 
proteins was examined. Levels of NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 8 (NDUFB8) of complex I, succinate dehydrogenase (ubiquinone) iron-
sulfur subunit (SDHB) of complex II, ubiquinol-cytochrome c reductase core protein 
II (UQCRC2) of complex III, ATP synthase alpha subunit 1 (ATP5A) and cytochrome 
c oxidase subunit I (mt-CO1) of complex IV all increased to some degree following 
exposure to NRTIs (Figure 3.3). The steady state level of mitochondrial transcription 
factor alpha (TFAM) decreased in cells exposed to NRTIs while levels of proteins 
involved in mitochondrial clearance, Pink1 and Parkin were unchanged and 
increased respectively (Figure 3.3) [115].  
Cells treated with rapamycin expressed lower steady state levels of NDUFB8, 
SDHB, UQCRC2, and mt-CO1, while levels of ATP5A were similar to control cells. In 
addition, ETC protein levels were not elevated when rapamycin-treated cells were 
exposed to NRTIs (Figure 3.3). Additionally, rapamycin-treated cells did not show 
changes in Pink1 or Parkin when exposed to NRTIs. Cells under methionine 
restriction expressed lower steady state levels of NDUFB8, and mt-CO1, while levels 
of ATP5A were similar to control cells. In addition, ETC protein levels were not 
elevated when cells were under methionine restriction and exposed to NRTIs. 
Additionally, cells under methionine restriction did not show changes in Pink1 but did 
display a decrease in Parkin when exposed to NRTIs. 
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Figure 3.3 Mitochondrial protein levels with NRTI treatment and interventions 
Western blot showing mito-profiler (CV-ATP5A, CIV-mtCOX1, CIII-UQCRC2, CII-SDHB, CI-
NDUFB8), TFAM, Pink and Parkin under NRTI, rapamycin and methionine restricted 
conditions. Actin is shown as a loading control.  
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An additional experiment was performed to determine if NRTIs have the 
ability to effect mitochondrial DNA replication. In order to answer this questions 
HCFs where depleted of their mtDNA via treatment with ethidium bromide and 
allowed to repopulate their mtDNA in the presence or absence of NRTI drugs. qPCR 
was used to determine mtDNA content as a ratio of mt-tRNA-leucine copy number 
and nuclear Beta-2-microglobulin copy number. The results from this study show 
that we were successful in depleting mtDNA in our Rho-0 condition and that the 
mtDNA repopulation rebounded after ethidium bromide was removed from the media 
however when ethidium bromide was released from the cells and the mtDNA was 
repopulated in the presence of the NRTIs the mtDNA content was less abundant 
than without the NRTIs present suggesting an inhibition of mtDNA replication under 
NRTI stress (Figure 3.4). 
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Figure 3.4 mt-DNA replication inhibition by NRTIs 
Quantification of mt-DNA/nuc-DNA ratio as performed by PCR. Expression values are 
relative to HCF control which is set to 1. Rho-0 indicates depletion of mt-DNA, Rho-0 
release indicates Rho-0 cells release from depletion culture settings, and Rho-0-NRTI 
release indicates release in the presence of NRTI drugs at 20ug/mL. * indicate significance 
from HCF control and # indicates significance from Rho-Release  p <0.05.  
 
 
3.3B Senescence response to mitochondrial dysfunction and protection 
by rapamycin and methionine restriction 
Molecular markers of the senescence program were examined following 
exposure to NRTIs (Figure 3.5). Levels of p53, p21 and p16 increased in fibroblasts 
exposed to NRTIs, In contrast, lamin B1, which is known to decrease during 
senescence [116], decreased in cells exposed to NRTIs. In rapamycin-treated cells, 
the levels of these senescence-associated proteins did not increase (or decrease in 
the case of laminB1) (Figure 3.5) and methionine restricted cells showed similar 
results. Intracellular levels of IL-6, a component of the senescence-associated 
secretory program (SASP), increased following exposure to NRTIs. Consistent with 
a block in the senescence program, rapamycin-treated and methionine restricted 
cells showed no increase in IL-6 following exposure to NRTIs (Figure 3.5).  We next 
examined the percentage of cells expressing the senescence marker, senescence-
associated β-galactosidase (SA-β-gal) following exposure to NRTIs. We observed a 
increase in the percentage of cardiac fibroblasts expressing SA- β-gal, with 10% in 
control cells and 85% in cells exposed to 20 ug/ml of NRTIs (Figure 3.5). Rapamycin 
treated and methionine restriction cultures showed little increase in SA-β-gal 
following NRTI treatment (Figure 3.6).  
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Figure 3.5 Protein levels of senescent markers after NRTI treatment and interventions 
Western blot showing p16, IL6, p53, p21 and LaminB1 under NRTI, rapamycin and 
methionine restricted conditions. Actin is shown as a loading control.  
 
  
  
57
 
Figure 3.6 Senescence associate beta-gal quantification  
Bar graph quantifying the percent of cells in culture in each condition that were positive for 
beta-gal staining. * shows significance between a culture setting with and without NRTIs. # 
shows significance from NRTI treatment with or without an intervention (methionine 
restricted conditions (1 and 3 mg/L restriction) and rapamycin conditions (1nM)) p <0.05. 
Grey bars are without NRTIs and black bars are with NRTIs. 
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3.3C Activation of mTORC1/p70S6K signaling in nucleoside/nucleotide 
analog induces senescence, which is prevented by either rapamycin 
and methionine restriction 
Based on the fact the TOR is a key regulator of senescence we wanted to 
evaluate how this signaling axis could be negatively affected by NRTIs. Due to 
recent findings suggesting that HDM2 is a downstream target of p70S6K [117] and 
our previous observations that the S6 kinase is activated in senescence in a growth-
factor-independent manner [118,119], we decided to investigate the possibility that 
HDM2 phosphorylation, mediated by p70S6K, might be a component of the cellular 
response to NRTIs (Figure 3.7 A). We first verified that exposure to NRTIs increased 
both p70S6K activity (by examining the phosphorylation status of the ribosomal S6 
protein) and phosphorylation status of HDM2. Phosphorylation of both the ribosomal 
S6 protein and HDM2 increased in cardiac fibroblasts following exposure to NRTIs 
(Figure 3.7 B). Consistent with the inhibition of senescence, rapamycin-treated 
cultures and methionine restricted cultures (1 mg/L) showed a complete lack of 
ribosomal S6 phosphorylation and no increase in HDM2 phosphorylation even in the 
presence of NRTIs (Figure 3.7). However, 3 mg/L methionine did still show in 
increase in both p70S6K and phosphorylation of HDM2.  
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Figure 3.7 TORC signaling under NRTI stress and interventions 
A) Depiction of phosphorylation of ribosomal S6 protein and HDM2 in response to NRTI 
exposure. B) Western blot showing phosphorylation status of the ribosomal S6 protein and 
HDM2 in response to NRTI exposure in human cardiac fibroblasts under control conditions, 
methionine restricted conditions (1 and 3 mg/L restriction) and rapamycin conditions (1nM).  
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3.3D ROS as a signaling molecule and inducer of senescence 
The dependence of NRTI-induced p70S6K activity on ROS was examined by 
treating cells exposed to NRTIs with mito-Q (a mitochondrial specific ROS 
scavanger) and examining ribosomal S6 phosphorylation. Both ribosomal S6 
phosphorylation and HDM2 phosphorylation were decreased when cells exposed to 
NRTIs were treated with mito-Q (Figure 3.8 A). Additionally, mito-Q-treated cells 
exhibited a lower level of mitochondrial ROS when exposed to NRTIs (Figure 3.8 C). 
Treatment with mito-Q also prevented the induction of senescence markers with 
decreased levels of p53, p21 and p16 as well as maintained levels of laminB1 
(Figure 3.8 B). In addition, the percentage of cells positive for SA-β-gal staining was 
reduced in cells treated with mito-Q (Figure 3.8 D).  
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Figure 3.8 mt-ROS scavenging as an NRTI intervention 
A) Represents an immunoblot analysis of the phosphorylation status of the ribosomal S6 
protein and HDM2 in cardiac fibroblasts cultured in the presence of mito-Q or the inactive 
carrier TPP for the duration of NRTI exposure. Cultures were exposed to NRTIs as 
described in Section 2, with the exception that one set of cultures was maintained in 
medium supplemented with Mito-Q while a second set of cultures was maintained in 
medium supplemented with the TPP control. The solid line separates individual 
immunoblots. Each immunoblot represents a minimum of two independent experiments with 
similar results and is shown with actin as a loading control. B) Represents an immunoblot 
analysis of the senescent markers p16, p21, p53 and LaminB1 in cardiac fibroblasts 
cultured in the presence of mito-Q or the inactive carrier TPP for the duration of NRTI 
exposure. C) Quantification of flow cytometry measuring mean fluorescence to detect 
mitochondrial ROS production in cardiac fibroblasts cultured in the presence of mito-Q or the 
inactive carrier TPP for the duration of NRTI exposure. D) Quantification of percent cells 
positive for SA-Beta-Gal in cardiac fibroblasts cultured in the presence of mito-Q or the 
inactive carrier TPP for the duration of NRTI exposure. * shows significance between a 
culture setting with and without NRTIs. # shows significance from NRTI treatment with or 
without an intervention p<0.05.  
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To determine whether increased ROS can directly induce phosphorylation of 
the ribosomal S6 protein, cardiac fibroblasts were placed in serum-free medium for 
48 hours to abrogate growth factor signaling that might influence mTORC1 activity. 
The cells were then exposed to hydrogen peroxide at concentrations ranging from 1 
to 400 μM for 2 hours. Both ribosomal S6 phosphorylation and HDM2 
phosphorylation were increased at the lower concentrations of hydrogen peroxide, 
with maximal activation at 50 μM. We observed inhibition of both ribosomal S6 
phosphorylation and HDM2 phosphorylation at high concentrations of hydrogen 
peroxide greater (800 μM, Figure 3.9). The loss of phosphorylation of the S6 protein 
corresponded with an enhanced mobility of the S6 protein (note greater mobility of 
S6 in extracts from cultures exposed to 600 and 800 μM hydrogen peroxide).  
 
 
Figure 3.9 Exogenous ROS as a TORC signaling molecule  
Serum-deprived cardiac fibroblasts were exposed to increasing concentrations of hydrogen 
peroxide (0-800 uM) for 2 hrs. western blot analysis shows phosphorylation status of S6 
ribosomal protein and HDM2 as well as an actin loading control. 
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3.3E Identifying similar paradigms in the context of replicative 
senescence 
As previously mentioned, our laboratory has reported that in senescent cells, 
phosphorylation of the ribosomal S6 protein is maintained in the absence of growth 
factor signaling, suggesting the activation of mTORC1 in this setting [119,120]. The 
role of mitochondrial ROS in this event was examined by treating senescent cardiac 
fibroblasts with the mitochondrial ROS scavenger mito-Q or by introducing a 
mitochondrial-targeted catalase. Initially, levels of mitochondrial and total cellular 
ROS were examined in late passage cells. This assessment revealed elevated 
levels of mitochondrial ROS and total cellular ROS in late passage cells (Figure 
3.10, A and B). Assessment of mitochondrial activity by Seahorse Bioanalyzer 
revealed elevated respiration, consistent with previous studies in senescent cells 
using isolated mitochondria [121] and with the effect of NRTIs. Bioanalyzer analysis 
indicated that both basal and maximal respiration, as well as ATP-linked respiration 
rates were significantly increased in senescent cells compared to early passage 
cells, as was proton leak (Figure 3.10, C-G). 
The progressive increase in ribosomal S6 and HDM2 phosphorylation during 
replicative senescence was verified in cardiac fibroblasts (Figure 3.10 H). These 
findings show that normal aging process involves ROS signaling downstream to 
mTORC1 and that NRTIs help to promote this same phenomenon as a means to 
promote aging. 
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Figure 3.10 Mitochondrial stress, TORC signaling and senescence in replicative 
senescence  
A&B) Levels of mitochondrial and total cellular ROS in early passage and senescent cardiac 
fibroblasts are presented. Gray bars represent cells maintained under standard culture 
conditions and black bars represent cells maintained in the presence of 1 nM rapamycin. C-
G) contain Seahorse Bioanalyzer analysis of mitochondrial function in human cardiac 
fibroblasts. Panel C contains a graphical representation of oxygen consumption rate 
normalized to cell number, as a function of time following the addition of the mitochondrial 
inhibitors oligomycin, FCCP, or a combination of rotenone and antimycin A. Panels D–G 
show calculated rates of (D) basal respiration, (E) maximal respiration, (F) ATP-linked 
respiration, and (G) proton leak. Bars marked with an asterisk represent values that are 
significantly different from relative control values at P<0.05 and bars marked with an # 
represent values that are significantly different between rapamycin-treated and untreated 
cells within the same treatment group (control or exposed to NRTIs). Each Seahorse 
experiment represents a minimum of three independent experiments with similar results. In 
Panel H, protein lysates derived from cells at increasing population doublings were probed 
for markers of senescence, p21 and p16, as well as the phosphorylated forms of the 
ribosomal S6 and HDM2 proteins. 
 
3.4 DISCUSSION 
 
 The above findings show that NRTIs are inducing mitochondrial dysfunction 
such that cells treated with these drugs have altered ETC activity/efficiency, 
increased membrane potential and are producing excessive amounts of ROS. We 
show novel evidence that this ROS is acting as a signaling molecule to increase 
downstream effectors like TORC1, HDM2 and p53. This elevated ROS signaling 
leads to the progression of senescence through p53 mediated signaling. As a 
consequence we observed all the canonical signs of senescence including increase 
SA-β-Gal, increase p16 and p21 and decreased levels of Lamin B1 following NRTI 
  
66
treatment. These negative cellular side effects induced by NRTIs were effectively 
prevented when cells were co-cultured with either rapamycin or methionine 
restriction. These drugs are known to have anti-aging properties and here we further 
indicate them as having the ability to promote mitochondrial homeostasis. 
 Our evaluation of the electron transport chain revealed that the NRTIs are 
inducing an ETC inefficiency. We see elevated basal and maximal respiration, which 
indicates more oxygen being consumed to pump protons across the inner-
mitochondrial membrane and is reflected in our mitochondrial membrane potential 
measurements. However, we also see an increase in proton leak, which suggests 
that the ETC is working very hard but losing energy to proton leak and not effectively 
using its proton gradient to make ATP. This effect could be explained by an altered 
ETC subunit formation. Literature evidence suggests that inefficiencies in ETC 
proton/electron utilization could be due to a lack of super complex formation [122]. 
Super complexes are large enzyme complexes made up of different subsets of 
enzymes from the ETC and are formed when ETC subunits locate in close proximity 
to one another to allow easier passage of electrons from one complex to the next. 
There is a potential that treatment with rapamycin and methionine restriction could 
be promoting the formation of super complexes to allow for continued ETC efficiency 
even in the presence of stressors like the NRTIs. 
In terms of the activation of mTORC1 in a setting where proliferation is 
inhibited, there are a growing number of reports of aberrant activation of mTOR 
signaling in senescence and aging. For example, a multicenter study originally 
intended to examine components of the IGF-1 axis during aging, identified increased 
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ribosomal S6 protein phosphorylation as the most consistent finding in both mouse 
and human muscle during aging [123]. More recently, an increase in phosphorylation 
of the ribosomal S6 protein has been described in aged liver and heart [124,125]. 
Similarly, in a mouse model of Hutchinson-Gilford Progeria Syndrome, mTORC1 
activity increased relative to control animals [126].  Interestingly, an increase in 
mTOR, Raptor, and ribosomal S6 phosphorylation have been reported in brain 
tissue of patients with severe Alzheimer’s Disease, relative to those with mild or 
moderate disease [127]. A more direct link to mitochondrial function and ribosomal 
S6 phosphorylation has been described in cardiac myocytes, where targeting of the 
mitochondrial exonuclease EXOG led to increases in mitochondrial oxygen 
consumption, ATP-linked respiration, and ribosomal S6 phosphorylation similar to 
those observed in this study in response to NRTIs [128].  
These findings support the idea that NRTI drugs are inducing mitochondrial 
dysfunction, which then triggers senescence. This paradigm suggests a new role for 
the mitochondria as a mediator of senescence. The senescence induced by NRTI 
treatment could be an important aspect when considering the development of the 
age-related comorbidities associated with HIV. Interestingly, we show that 
rapamycin and methionine restriction can help combat the deleterious effects of 
NRTIs in-vitro. This suggests a potential role for these interventions in the clinic to 
combat the age-related comorbidities of HIV. In order to allow for bench to bedside 
transition of these interventions we need to understand exactly how they might be 
effecting normal cell processes. In the next chapter we have embarked on a 
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transcriptional analysis of cells treated with these interventions in order to elucidate 
their therapeutic mechanisms. 
 
 CHAPTER 4: SENESCENCE INTERVENTIONS: THERAPEUTIC MECHANISMS 
FOR RAPAMYCIN AND METHIONINE RESTRICTION. 
 
4.1 ABSTRACT  
 
Cellular senescence has emerged as a key component of the aging process.  
The burden of senescent cells increases with age and these cells are thought to 
contribute to age-related dysfunction and susceptibility to disease.  Strategies to 
selectively target senescent cells have been found to improve late-life function in 
several animal models and there is evidence that interventions that extend lifespan, 
such as caloric restriction, methionine restriction, and rapamycin treatment reduce 
the burden of senescent cells in the organism.  In cell culture models, both 
rapamycin treatment and methionine restriction delay senescence.  In this study, we 
report that a combination of rapamycin and methionine restriction dramatically 
extends lifespan and abrogates the senescence program.  It appears that metabolic 
adaptation in these conditions leads to greater metabolic flexibility and a reduction in 
molecular damage such as mitochondrial ROS and endogenous DNA damage.  
Transcriptome-wide analysis confirms the abrogation of the senescence program in 
cultures exposed to combined methionine restriction and rapamycin treatment.  
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These results suggest that it may be possible to modify or abrogate the senescence 
program in human cells through metabolic interventions. 
 
4.2 INTRODUCTION  
 
Given the emerging role of senescence as a mediator of age-related dysfunction, 
the reproducible manner in which human diploid fibroblast undergo senescence 
represents a model system which can be used to identify agents and treatments that 
delay or alter the senescence program in a beneficial manner. Our lab and others, 
have reported that non-genetic interventions which extend lifespan, such as 
inhibition of mTORC1 through treatment with rapamycin or restriction of methionine, 
delay senescence in human diploid fibroblasts [43,48,49].  It appears that rapamycin 
extends cellular lifespan, at least in part, through a reduction in mitochondrial stress 
and an improved metabolic balance [44]. Similarly, methionine restriction has been 
reported to impact mitochondrial function and shift metabolism towards fat utilization 
in mice and to reduce complex IV activity and mitochondrial protein expression in 
human diploid fibroblasts[49,54], effects which may be related to an activation of the 
retrograde response [48]. Basal fatty acid oxidation is reduced with age [129], while, 
the metabolic profile of mice placed on methionine restriction is improved, 
triglyceride content of multiple tissues is reduced, and mitochondrial content and 
biogenesis are increased [130].   
Mitochondrial are central to cellular metabolism and homeostasis, contributing to 
ATP production and the regulation of cellular redox status as well as the production 
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of biosynthetic precursors.  In addition, cellular homeostasis requires a dynamic 
communication between the mitochondria and the nucleus that regulates both gene 
expression and cellular processes [131].  We have found that mitochondrial 
dysfunction resulting in increased reactive oxygen species (ROS) activates the 
cellular senescence program [132] while recent evidence also suggests that cellular 
senescence stimuli integrate altered mitochondrial function to stabilize the senescent 
phenotype [133].  This suggests that mitochondrial dysfunction may not only 
accompany but also serve as a trigger for cellular senescence.  However, the 
signaling pathways that preserve or disrupt mitochondrial function and influence 
cellular aging and senescence are not fully elucidated.  Our laboratory has shown 
that treatment of human fibroblasts with a nanomolar concentration of rapamycin, a 
pharmacological inhibitor of mTORC1, stimulates mitochondrial retrograde signaling 
to coordinate mitochondrial biogenesis with clearance, which results in extended 
replicative lifespan and resistance to mitochondrial stress [43,44].  Thus, improved 
mitochondrial homeostasis is a potential mechanism to delay or prevent cellular 
senescence. Similar to the benefits of rapamycin treatment, many studies have 
highlighted increased autophagy, extended lifespan and improved mitochondrial and 
metabolic profiles following methionine restriction [50-54].  These results suggest 
that a possible mechanism for the lifespan-extending properties of both rapamycin 
treatment or methionine restriction (metR) is delayed cellular senescence due to 
improvements in mitochondrial function.    
In this study, we have examined the impact of treatment with rapamycin 
under conditions of methionine restriction.  We find that the combined treatment 
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substantially delays cellular senescence further than either regimen alone.  Profound 
changes in metabolism and autophagy are induced, endogenous DNA damage is 
reduced and transcriptome analysis reveals that cultures subjected to both 
methionine restriction and rapamycin treatment do not activate the senescence 
program even at high population doublings. 
 
4.3 RESULTS 
 
4.3A A combination of methionine restriction and rapamycin treatment 
extends replicative lifespan  
Human cardiac fibroblasts (HCFs) were cultivated in either standard culture 
conditions [134] or in methionine restricted media in the presence or absence of 
rapamycin.  Methionine was reduced in the culture medium from 30 mg/L to 1 mg/L 
(97% reduction).  Rapamycin at 1nM was added to a parallel set of cultures in each 
case.  The lifespan curve for these cultures was determined by direct calculation of 
the cumulative number of population doublings (cPDL) as to track the onset of the 
Hayflick limit as a reflection of senescence. We find a dramatic increase in cPDL 
relative to standard culture conditions as seen in Figure 4.1.  Rapamycin treated 
cultures achieved a cPDL of 78 as compared to cPDL 54 under control conditions, 
consistent with our previously published results [43,119].  Methionine restriction had 
an acute negative impact on growth but allowed cells to achieve a greater number of 
doublings than standard conditions (cPDL 59 versus cPDL54).  Complete removal of 
methionine from the media composition leaving only serum derived methionine 
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drastically reduced cell growth.  These results are consistent with published reports 
on the impact of methionine restriction on the lifespan of human fibroblasts [48,49].  
Surprisingly, rapamycin treatment in the presence of methionine restriction produced 
both growth benefits and significantly increased lifespan well beyond either 
treatment alone.  The cells cultivated in the combination condition continued to 
proliferate for up to one year in culture reaching a cPDL of 91 and cultures in which 
methionine was completely excluded from the media composition were able to 
achieve a cPDL of 69 in the presence of rapamycin.  In addition, the growth 
phenotype of late passage cells grown in methionine restricted conditions with 
rapamycin differed from cultures in standard conditions. Typically, cultures which 
enter senescence show a gradual loss of cell number due to loss during harvesting 
and reseeding, which is required every 2-3 weeks (note downward trend in control 
cultures in Figure 4.1 at the end of lifespan). In contrast, the rapamycin/methionine 
restricted cultures were doubling at an extremely slow rate (less than one doubling 
every 14 days) but did not show a reduction in cell number. Thus, the cultures retain 
sufficient replicative capacity to maintain equilibrium. At 36 weeks the cells become 
a limiting resource, so cultures were terminated to avoid eventual loss to 
contamination and total RNA was isolated to allow an analysis of gene expression.  
This lifespan was repeated 4 times with very similar results, cultures under standard 
conditions undergoing senescence at cPDLs ranging from 50-56, methionine 
provided a small increase of 5-8 PDs, rapamycin provided a larger increase of 10-15 
PDs and the combination of methionine restriction and rapamycin provided the 
largest increase ranging from 29-39 PDs. 
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Figure 4.1 A combination of methionine restriction and rapamycin treatment 
increases the replicative lifespan of human cardiac fibroblasts beyond methionine 
restriction or rapamycin treatment alone.  
Representative lifespan analysis of human cardiac fibroblasts maintained under the 
following conditions with or without 1 nM rapamycin (Rapa): standard culture conditions 
(Ctrl, 30 mg/L methionine); methionine-restricted (MetR, 1mg/L methionine). Treatments 
were initiated at PD 27 using cultures maintained under control conditions from a PD of 3 as 
indicated by the arrow. Lifespan analysis was repeated 3 times with similar results and was 
performed at 6% oxygen with similar results.  Maximum lifespan was significantly increased 
compared to control cultures in the rapamycin treated (Rapa, P=0.029) and methionine 
restriction with rapamycin treatment (Rapa+MethR, P=0.023) when the results of 3 lifespan 
curves were analyzed together. Growth rates of the MethR 1mg/L cultures were significantly 
reduced relative to control cultures (differences in growth rate over 5 weeks: P=0.004 for 
MethR 1mg/L). Addition of rapamycin to these cultures increased the growth rate so that 
there was no statistical difference from controls. 
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4.3B RNASeq 
In order to obtain a global assessment of the impact of methionine restriction 
and rapamycin on cellular processes, we performed a series of RNA sequencing 
analyses.  RNA isolated from early passage cells, and late passage or senescent 
cells were analyzed in comparison to methionine restricted, rapamycin treated and 
the combination of methionine restricted and rapamycin treated. The RNA from 
these cells was isolated at the same point in lifespan when the late passage cultures 
were entering senescence, from early passage cells at population doubling 25, and 
from the methionine restricted and rapamycin treated cells at week 36. Prior to 
differential expression analyses the RNA sequence data was subject to a series of 
validation analyses.  We wanted to confirm that the RNA samples run in replicates 
were indeed similar to one another and that the two RNA-Sequencing runs were not 
markedly different from one another.  When plotted against one another all triplicate 
gene read counts correlated with adjusted R-Squared values > 0.98. To confirm 
there was no sequencing bias between RNA-sequencing preps and runs, we ran 
one RNA sample (EarlyPass_A) through both runs, when gene read counts were 
plotted against one another the adjusted R-Squared values was 0.994, suggesting 
that these two samples were extremely similar despite being handled separately 
(Figure 4.2 A-D).  As an additional validation, the mRNA expression values from the 
RNA Seq data were compared to previously acquired results via NanoString 
analysis, which provides direct mRNA counts using 2 contiguous fluorescent labeled 
probes for each mRNA species.  The expression of 44 genes for both mRNA 
counting methods were plotted against each other for each of the 5 treatments and 
we confirmed that these two methods did indeed corroborate the same findings with 
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R-Squared values ranging from 0.37-0.53 for each treatment comparison (p values 
5.5x10-6 to 1.6x10-8, Figure 4.3 A-F).   
 
 
Figure 4.2 RNASeq Run Validation 
R derived dot plot showing the Log10 of the Reads PerKilobase of transcript per Million 
mapped reads on each axis. A-C) These plots display normalized RNASeq expression 
values comparing each sample to the others in the triplicate for Run 1, EarlyPass sample D) 
This plot displays normalized RNASeq expression values comparing an identical RNA 
sample (EarlyPass_A =EarlyPass_1) run in 2 separate sequencing runs (Run 1 on the X 
axis and Run 2 on the Y axis). In the upper right corner of the plot the statistics from linear 
regression analysis show that the correlation of gene expression between the 2 runs is as 
follows: adjusted R-squared:  0.9944,F-statistic: 4.165e+06 on 1 and 23391 DF, p-value: < 
2.2e-16.  
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Figure 4.3 Nanostring vs RNASeq Validation 
A-E) R derived dot plot showing the Log10 of the Reads Per Kilobase of transcript per 
Million mapped reads on each axis. These plots display normalized RNA expression values 
comparing Nanostring and RNASeq methods of RNA counting (Nanostring on the X axis 
and RNASeq on the Y axis). Each dot plot shows the comparison of gene expression for 
each treatment group in the study (EarlyPass, LatePass, RapaCtrl, MethRes and Combo). 
F) Linear regression analysis statistics for each comparison are listed. 
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After validation, basic differential expression analyses were performed on the 
data set as a whole to understand the data set before individual treatment 
comparisons were done. PCA analysis was conducted to further distinguish the 
relative similarity of samples in our study. This PCA was conducted using the top 
500 genes in our dataset with the highest variance across all samples and was able 
to model about 50% of the variability in gene expression in our data as see by PC1. 
In the PCA plot in figure 4.4 the late passage samples group separately from the 
early passage samples as expected.  The rapamycin treated alone and the 
combination treated cells cluster between the early and late passage cells and seem 
to group by which RNASeq run they were performed in. Interestingly, we see distinct 
clustering of both methionine restricted cells and the very late passage combination 
cells, confirming the sample distance matrix analysis, which indicated that the very 
late passage methionine restricted and rapamycin treated cultures have a unique 
transcriptional profile not related to senescence.  We expanded the transcriptome 
comparison to produce a sample distance matrix (SDM) based on the overall 
similarity of gene count profiles between each sample and calculated Euclidean 
distances within DESeq2 (Figure 4.5). The differences in sample distance can be 
appreciated in the SDM in Figure 4.5 by examining the numerical values. These 
values correlate with the intensity of shading, where darker blue indicates a greater 
similarity or smaller Euclidean distance. The greatest similarity is found on the 
diagonal, as samples are most highly related to themselves. Samples within 
replicates fall within a Euclidean distance of approximately 30-50, whereas more 
distantly related samples produce a Euclidean distance of 150 or greater. At cPDL 
91, cultures exposed to both methionine restriction and rapamycin treatment 
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exhibited a Euclidean distance of greater than 180 to both early passage and late 
passage control cultures, indicating little similarity to either state. 
 
 
Figure 4.4 RNASeq PCA plot 
PCA plot of all RNASeq samples run. Plot represents the general similarity of each sample 
in terms of their top 500 differentially expressed genes. Circles represent samples run in the 
first round of sequencing and triangles represent the samples run in the second round of 
sequencing. Each treatment is color coded. 
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Figure 4.5 Sample Distance Matrix 
Graphical representation of an analysis of Euclidean distance between cell cultures.  The 
gene count profile from each RNASeq sample was compared to all other RNASeq samples 
to evaluate general similarity. Darker blue shading indicates a shorter Euclidean distance 
(greater similarity) compared with lighter blue shading which indicates a longer distance. 
Each block contains the numerical Euclidean distance for the given comparison, with a 
higher number indicating a greater distance. Late passage (cPDL 91) cultures maintained 
under the combination of methionine restriction and rapamcyin treatment are labeled 
OldRapaMR.  Samples labeled EarlyPass represent values from early passage (PDL25) 
cells. Samples labeled RapaCtrl contain values from cultures treated with only rapamycin. 
Samples labeled MetR contain values from methionine-restricted cultures. Samples labeled 
RapaMetR contain values from cultures exposed to both methionine restriction and 
rapamycin. The diagonal shows zeros indicating that the sample compared with itself is not 
at all dissimilar. Samples with names ending in a letter were included in RNASeqRun 1. 
Samples with names ending in a number were included in Run 2.   
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Next, we confirmed that RNA isolated from the late passage cells displayed a 
gene expression profile consistent with senescence by examining the expected 
increase in mRNA levels of p21, p16, IL6, IGF1R, IGFBP5 and 7 and decreased 
mRNA levels of lamin B1.  A volcano plot of differentially expressed genes between 
early and late passage cells is presented in Figure 4.6A and corresponding table of 
statistics for canonical senescence genes are displayed in Figure 4.6 B.  In addition, 
we wanted to compare the methionine restricted, rapamycin treated, and the 
methionine restriction/rapamycin combination to one another to identify uniquely 
expressed genes under the combination methionine restricted/rapamycin condition.  
A curated list of genes uniquely differentially expressed at a log 2 fold change with 
an adjusted p value <0.05 in the methionine restricted/rapamycin treated cells was 
established by creating 3 lists of differentially expressed genes (p<0.05 and 
L2FC>|1|) for each condition (rapamycin alone, methionine restriction alone, and the 
combination of methionine restriction and rapamycin) against early passage control 
cultures at week 4 of the growth curve in Figure 4.1.  Each of these lists were 
compared to one another as depicted in the Venn-Diagram in figure 4.7. The genes 
that were differentially expressed in the combination but not in either rapamycin 
alone or methionine restriction alone were considered “uniquely expressed in the 
combo” and subjected to David functional annotation analysis. No functional 
pathways were identified among the genes with reduced expression. However, 
seven pathways were defined to be up-regulated (Table 4.1). Among the DAVID 
pathways identified to be up regulated and most related to nutrient sensing were: 
lysine degradation, glycine, serine, threonine metabolism, and thyroid hormone 
signaling. When we examined the genes that the DAVID program identified as 
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belonging to these pathways, each pathway included several related to methionine 
metabolism. For example, the differential expression of genes related to the 
recycling of methionine from homocysteine was the basis for the identification of the 
glycine, serine, threonine metabolism pathway. These genes included betaine-
homocysteine S-methyltransferase (BHMT) which catalyzes the synthesis of 
methionine using homocysteine and the methyl donor betaine in the methionine 
cycle, as well as cystathionine gamma-lyase (CTH), which is also involved in 
homocysteine metabolism [135]. Additional genes contributing to the identification of 
this pathway included DMGDH, PSAT1, and GLDC.  The thyroid hormone signaling 
pathway was identified by the differential expression of 7 genes including 6-
phosphofructo-2-kinase/fructose-2,6-Biphosphatase 2 (PFKFB2), a critical regulator 
of glycolysis. Additional genes contributing to the identification of this pathway 
included MED13L. NOTCH1, NOTCH2, MDM2, Myc, and THRB. Finally, 
differentially expressed genes in the lysine degradation pathway included ASH1L, 
SETD1B and KMT2D all of which are significantly increased in cultures treated with 
methionine restriction and rapamycin treatment. These enzymes act in concert as 
methyltransferases to produce trimethyl lysine as the first steps in a direct pathway 
to produce carnitine. Carnitine is an indispensable mediator of intermediary 
metabolism which is required to transport long chain acyl groups across the 
mitochondrial membrane by carnitine palmitoyltransferase (CPT1) to facilitate beta-
oxidation [136]. In our transcriptome analysis, CPT1 is increased significantly by the 
combination of rapamycin and methionine restriction in both the early passage and 
late passage settings versus early passage controls (1.6 fold and 4 fold P=0.0095 
and 6.2x10-4, respectively).  
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Figure 4.6 Human cardiac fibroblasts exposed to methionine restriction and 
rapamycin treatment do not activate the senescence program. 
A) Volcano plot showing differential gene expression analysis for 22,349 genes, including 
senescence-associated genes, conducted at Weeks 4 and 23 of lifespan in human cardiac 
fibroblasts grown under standard culture conditions (see FIG 1).  Count tables were 
evaluated by DESeq2 using R as described in Materials and Methods. The graph compares 
the log 2-fold change in sequencing counts (abscissa) with the (-)log 10 of the p-value for 
each comparison.  A subset of genes associated with the senescence program are labeled, 
B) shows the DESeq2 differential expression values of those genes comparing LatePass to 
EarlyPass. B) Corresponding table with senescence gene DESeq2 expression values listed.  
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Figure 4.7 Differential expression analysis identifying unique genes in cell treated 
with the combination treatment. 
Lists of differentially expressed genes with a minimum of a log 2-fold change of 1 (or fold 
change of 2) in expression and a corrected P-value of 0.05 were generated using DeSeq2 
and incorporated into the Venn diagram. Differentially expressed genes were derived by 
comparison of rapamycin-treated versus early passage (RC_EP), methionine-restricted 
versus early passage (Met_EP), and combination methionine-restricted and rapamycin-
treated versus early passage (RM_EP) cultures. Numbers represent the number of genes 
that are differentially expressed under each condition compared with early passage cells. 
Areas of overlap indicate genes that are common to the overlapping treatments and areas 
with no overlap represent differentially-expressed genes that are unique to that treatment. 
Differentially-expressed genes unique to the methionine restriction/rapamycin treatment 
combination were divided into lists based on expression level relative to early passage cells; 
those showing increased expression relative to early passage (UP) and those with 
decreased expression (DOWN). See Table 4.1 for DAVID pathway analysis breakdown. 
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KEGG Pathway 
(Unique to Combo) 
Genes Gene Names P-value Adj  P 
Glycine, serine, 
threonine metabolism 
5 BHMT, CTH, DMGDH, GLDC, PSAT1 3.2x10-3 0.28 
Axon guidance 8 EPHA4, ROCK2, NTN2, PAK2, 
PLXNA2, PPP3R1, SEMA3C, UNC5B 
3.8x10-3 0.42 
Thyroid hormone 
signaling 
7 PFKB2, MDM2, MED13L, NOTCH1, 
NOTCH2, THRB, MYC 
9x10-3 0.40 
Taste transduction 4 SCNN1A, TAS1R3, TAS2R31, 
TAS2R5 
3.4x10-2 0.71 
Lysine degradation 4 ASH1L, SETD1B, KMT2D, 
COLGALT2 
4.8x10-2 0.8 
T cell receptor 
signaling pathway 
 5 FOS, PAK2, PPP3R1, PTPRC, TEC 7.9x10-2 0.9 
Proteoglycans in 
cancer 
7 MDM2, ROCK2, TIAM1, ANK2, 
ERBB3, MYC, VEGFA 
9.6x10-2 0.91 
Table 4.1: Pathways uniquely up-regulated in the combination treatment  
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 Additionally these enzymes have been implicated in telomere protection by 
modifying telomeric chromatin and interacting with p53, and the shelterin complex to 
regulate telomeric transcription and stability [137,138]. To identify if the up-regulation 
in methyltransferases could be contributing to telomere protection we set out to 
determine the extent of TERRA (Telomere repeat containing RNA) expression in the 
combination cells. We did this one of two ways first by interrogating the RNASeq 
reads to identify the number of reads that contains a telomeric repeat and next by 
preforming an RNA dot blot and probing with a P32-labelled oligonucleotide for 
TERRA. Interrogating the RNASeq reads showed that the combination treated cells 
had similar TERRA levels as the control early passage controls and that the 
combination cells grown to old age had higher TERRA levels than control late 
passage cells (Figure 4.8 A). The dot blot analysis showed slightly different results in 
that the combination cells had the higher level of TERRA expression than the control 
early passage cells (Figure 4.8 B). This data suggest that further interrogation of 
telomere structure, maintenance and damage could provide valuable insight into 
mechanisms for longevity assurance.  
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Figure 4.8 TERRA expression quantification 
A) Interrogation of RNASeq reads quantifying the number of reads contain 4 or more 
consecutive TERRA repeats (TTAGGG). B)  RNA dot blot quantification of phosphorimager 
intensities for TERRA P32 labels probe and normalized to 28S P32 labels probe as a 
loading control. Data shown is also normalized to EarlyPass (Set to 1). * indicates 
significance compared to EarlyPass p <0.05.   
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Further analysis was preformed to understand the unique gene expression 
profile of the combination treated cells when they reach an extended lifespan (week 
36). To do this analysis the old combination cells were compared to every other 
treatment in the study and a list of differentially expressed genes was established 
using DESeq2. With a threshold of an absolute value L2FC (log2fold change) of 2.5 
we identified 1,756 differentially expressed genes, 266 genes up and 1,490 genes 
down regulated. A DAVID pathway analysis was preformed and 10 pathways were 
identified to be affected by the up-regulated genes (Table 4.2) and 57 pathways 
were identified to be effected by the down-regulated genes. To narrow down the 
effected pathways of the down-regulated genes only the top 250 genes were used in 
the pathway analysis. A total of 12 pathways were detected. The top pathway that 
was up regulated was the ribosome pathway, this list consisting of genes that 
encode for both nuclear and mitochondrial ribosomal proteins. Additional up 
regulated pathways included pyrimidine metabolism, vascular smooth muscle 
contraction, oocyte meiosis, cell cycle, progesterone-mediated oocyte maturation, 
purine metabolism, oxidative phosphorylation, VEGF signaling and MAPK signaling. 
The 12 pathways that were down regulated included renin secretion, cGMP-PKG 
signaling, ovarian steroidogenesis, calcium signaling, cAMP signaling, retinol 
metabolism, PI3K-Akt signaling, pathways in cancer, cytokine-cytokine receptor 
interaction, Rap1 signaling, protein digestion and absorption and pancreatic 
secretion (Table 4.3). Additionally it is important to note that although lysine 
degradation is not one of the top 10 up-regulated pathways, the methyltransferases 
that are unique to the combination cells at mid-lifespan are up-regulated even more 
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drastically at this later stage in the lifespan from 2 fold to more than 10 fold, 
suggesting a continued role in cellular homeostasis.  
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KEGG Pathway  Genes Gene Names P-value Adj  P 
Ribosome 13 MRPL12, MRPL14, MRPL23, RPL18A, 
RPL22L1, RPL35, RPS10, RPS15A, RPS2, 
RPS26, RPS5, RPSA 
7.7x10-7 9.9x10-5 
Pyrimidine metabolism 7 POLD2, POLE4, NME1, POLR2L, CDA, 
DCTPP1, TK1 
4.6x10-3 0.26 
Vascular smooth muscle 
contraction 
7 ACTA2, ACTG2, ADORA2B, MYL6, MYL9, 
PPP1R14A, RAMP1 
8.9x10-3 0.32 
Oocyte Meiosis  6 CDC20, CDC25C, PTTG1, PLK1, PKMYT1, 
RPS6KA1 
2.4x10-2 0.54 
Cell Cycle 6 CDC20, CDC25C, CCNB2, PTTG1, PLK1, 
PKMYT1 
3.9x10-2 0.64 
Progesterone- mediated 
oocyte maturation 
5 CDC25C, CCNB2, PLK1, PKMYT1, RPS6KA1 4.2x10-2 0.6 
Purine Metabolism 7 POLD2, POLE4, NME1, POLR2L, APRT, GMPR, 
ITPA 
4.9x10-2 0.6 
Oxidative 
Phosphorylation 
6 ATP5I, ATP5J2, NDUFA11, NDUFA13, 
NDUFB7, COX7A2 
5.0x10-2 0.56 
VEGF signaling 
pathway 
4 HSPB1, RAC2, RAC3, SPHK1 6.4x10-2 0.61 
MAPK signaling 
pathway  
8 ECSIT, DUSP2, FGF1, HSPB1, NGF, RAC2, 
RAC3, RPS6KA1 
8.9x10-2 0.7 
Table 4.2: Pathways uniquely up-regulated in the late passage combination treatment  
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KEGG Pathway Genes Gene Names P-value Adj  P 
Renin secretion 7 CACNA1D, CLCA2, EDNRA, 
ITPR1, PDE3A, PDE3B, KCNJ2 
5.0x10-4 8.2x10-2 
cGMP-PKG signaling 
pathway 
9 CACNA1D, EDNRA, EDNRB, 
ITPR1, PDE3A, PDE3B, ATP1B2, 
ADRA2A, TRPC6 
4.8x10-3 0.33 
Ovarian steroidogenesis 5 BMP6, CYP1A1, HSD17B2, 
IGF1, PTGS2 
2.0x10-3 0.34 
Calcium signaling 
pathway 
9 GNAL, EDNRA, EDNRB, 
CACNA1D, CACNA1G, CHRM2, 
ITPR1, PRGFRA, PTGER3 
3.6x10-3 0.27 
cAMP signaling pathway 9 ATP1B2, CACNA1D, CHRM2, 
CFTR, EDNRA, PTGER3, 
PDE3A, PDE3B, PDE4D 
3.6x10-2 0.36 
Retinol metabolism 5 ADH1B, ALDH1A1, CYP1A1, 
CYP26B1, CYP3A7 
2.0x10-2 0.43 
PI3K-Akt signaling 
pathway 
12 KITLG, TEK, ANGPT4, CHRM2, 
COL4A4, COL6A5, FGF10, GHR, 
IGF1, KDR, PDGFRA, TNXB 
4.9x10-2 0.40 
Pathways in cancer 13 KITLG, FGF10, EDNRA, 
EDNRB, IGF1, PDGFRA, 
PTGER3, COL4A4, WNT4, 
DAPK1, PTGS2, TGFBR1, 
ZBTB16 
5.3x10-2 0.37 
Cytokine-cytokine 
receptor interaction 
9 KITLG, PDGFRA, TGFBR1, 
ACKR3, IL1R1, IL18R1, IL6ST, 
KDR, GHR 
3.6x10-2 0.43 
Rap1 signaling pathway 8 KITLG, FGF10, IGF1, DOCK4, 
PDGFRA, TEK, ANGPT4, KDR 
3.2x10-2 0.57 
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Protein digestion and 
absorption 
5 ATP1B2, ACE2, COL4A4, 
COL6A5, COL14A1 
2.0x10-2 0.55 
Pancreatic secretion 5 ATP1B2, RAB27B, CLCA2, 
CFTR, ITPR1 
2.0x10-2 0.58 
Table 4.3: Pathways uniquely down-regulated in the late passage combination 
treatment  
 
4.4 DISCUSSION  
 
These findings show that combining rapamycin and methionine restriction in-
vitro extends cellular lifespan to a larger extend than either intervention given alone 
and reveals a potential mechanism for senescence evasion that could be useful in 
developing clinical interventions. Transcriptome analysis of methionine restriction 
and rapamycin treated cultures revealed an impact on several metabolic pathways 
relating to methionine utilization and we find an enhanced ability to maintain oxygen 
consumption rates when cultures are challenged to alternate between a variety of 
carbon sources (Manuscript in preparation). We interpret this to indicate an 
enhanced ability to maintain reducing equivalents and biosynthetic precursor pools 
that are generated by intermediate metabolism, and we postulated that the 
augmentation of these precursor pools may alleviate endogenous DNA damage and 
limit senescence by alleviating the sustained DNA damage response that serves as 
a trigger for senescence. Interestingly, levels of the mRNA for the catalytic subunit of 
ribonucleotide reductase are elevated in the methionine restricted and rapamycin 
treated cultures supporting an increase in the production in nucleoside precursors. 
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Endogenous DNA damage can result from several processes including transcription 
and DNA replication, particularly in repetitive regions of the genome such as 
telomeric regions. This interpretation was supported by the preliminary data showing 
TERRA expression seems to be elevated in cells treated with methionine restriction 
and rapamycin. The methyltransferase expression levels seen in the RNASeq 
prompted the TERRA expression experiments due to their non-canonical role in 
telomere chromatin structure and TERRA expression [137,138]. Telomeric structure 
and stability are crucial elements that can influence a cells susceptibility to senesce. 
As mentioned in chapter 1 section 1.4, cellular senescence can be triggered by 
repeated rounds of the cell cycle resulting in continual shortening of the telomeres 
which leads to a chronic and detrimental DNA damage response. Our data indicates 
that cells treated with methionine restriction and rapamycin up-regulate pathways 
that potentially promote TERRA expression as a means to protect from telomeric 
damage. This theory may, in part, explain the vast lifespan extension seen with this 
treatment. 
Overall, these findings suggest that human cells have a much greater 
plasticity in terms of the senescence program than previously realized. It appears 
that the combination therapy creates a unique environment of metabolic flexibility 
coupled with efficient autophagic flux to better provide cells with the precursors they 
need for optimal cellular function. mTOR inhibition by rapamycin is known to vastly 
up-regulate autophagy for proper repurposing of intracellular stores [139], while the 
methionine restricted state forces the proper utilization of intracellular stores. This 
interplay creates a unique metabolic state that can provide nuclear genetic 
machinery with ample resources to maintain genome integrity. How this relates to 
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chromatin structure and impairment of chromatin remodeling typical of senescence 
may be explained by the fact that the methyltransferases identified by DAVID 
analysis not only play a role in lysine degradation and carnitine synthesis, but also 
have a role in H3K4 methylation. Trimethylation of H3 is one of the strongest marks 
of open chromatin and it is not surprising that a shift towards more open chromatin 
would prevent senescence associated remodeling and the intracellular 
concentrations of S-adenylmethionine are in the range of the Km for the 
methlytransferases [130,140], marking shifts in methionine concentrations potentially 
meaningful in terms of enzymatic activity.  Additionally these methyltransferases are 
also implicated in histone methylation in telomere regions [141] further supporting an 
impact on the senescence program. This connection between metabolic enzymes 
and chromatin remodeling may underlie the effect of this unique metabolic state on 
the global chromatin remodeling associated with the senescence program.  
As mentioned previously these methyltranferases have a well-defined role in 
the production of carnitine from the breakdown of lysine. Carnitine’s canonical role is 
to transport long chain fatty acids into the mitochondria for fuel. The combination 
treatment may use this as a mechanism for maintaining mitochondrial homeostasis 
and assuring metabolic flexibility. Interestingly, studies done in animals and humans 
shows an age related decline in carnitine and an associated decrease in the integrity 
of the mitochondrial membrane [57]. This supports the theory that the combination 
treatment is maintaining mitochondrial integrity via altering enzymes in the carnitine 
synthesis pathway. Additionally, carnitine is present at high levels in the brain and 
provides acetyl-equivalents for the production of the neurotransmitter acetyl-
choline[57]. Acetyl-choline is an important neurotransmitter in the brain that plays a 
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role in attention and memory functioning. The ability for the combination cells to up 
regulate enzymes involved in carnitine synthesis and downstream effect the 
production of acetyl-choline could indicate a potential therapeutic benefit for the 
treatment of memory deficits associated with HAND.  
This data and all subsequent work will help drive the idea that interventions 
like rapamycin and methionine restriction are viable therapies to treat age related 
diseases. Understanding how they alter gene expression and cellular function is 
crucial to achieving the optimal therapeutic effect. Further studies on manipulating 
the methyltransferases will show whether targeting these enzymes directly can still 
lead to senescence evasion and cellular homeostasis with age.  
 
CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
 
5.1 SUMMARY STATEMENT 
 
Overall this work highlights the need for adjuvant therapies to combat age 
related co-morbidities associated with the aging HIV population. It is known that 
fluctuating viral load coupled with long-term NRTI treatment creates an accelerated 
aging phenotype where patients show early onset neurocognitive decline and 
cardiovascular issues. Studying accelerated aging settings can help aid in gaining 
knowledge about treating the natural onset of aging diseases without having to wait 
many years for them to develop. The working model for this thesis culminates in a 
paradigm where NRTI drugs induce mitochondrial dysfunction, which acts as a 
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trigger for senescence. The accumulation of senescent cells in tissues will lead to 
the manifestation of premature aging like those seen in the context of HIV-
associated neurocognitive decline or HIV-associated cardiovascular disease. 
Interventions like rapamycin and methionine restriction are affective tools in-vitro to 
prevent the deleterious effects of NRTI drugs and delay the onset of senescence. 
Due to the beneficial effects seen in-vitro, these interventions have the potential for 
clinical application in settings where premature aging is induced (Figure 5.1). 
 
 
Figure 5.1 Thesis Working model 
This thesis work culminates in a paradigm where NRTI drugs induce mitochondrial 
dysfunction which acts as a trigger for senescence. The accumulation of senescent cells in 
tissues will lead to the manifestation of premature aging like in the context of HIV-associates 
neurocognitive decline. Interventions like rapamycin and methionine restriction are affective 
tools in-vitro to prevent the deleterious effects of NRTI drugs and delay the onset of 
senescence. Due to this finding, these interventions show a potential for clinical application 
in settings where premature aging is induced.  
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More specifically, this work highlights that mitochondrial dysfunction and 
senescence accumulation are important triggers for the progression of these age-
associated issues. This work further supports the role of mitochondria in aging by 
highlighting mitochondrial DNAs influence on HAND susceptibility and showing 
mitochondria as a key modulator of NRTI induced senescence in the context of the 
heart. Remarkably, treatments like rapamycin and methionine restriction abrogate 
these stressors and promote healthy cellular homeostasis. RNAseq analysis 
revealed that combining rapamycin and methionine restriction alters metabolism and 
helps to increase the expression on methyltransferases that are important for proper 
telomere protection, carnitine synthesis and H3K4 methylation. The changes in 
metabolism could be a key reason these cells live an extended healthy lifespan and 
do not undergo the canonical senescence reprogramming. Metabolism changes 
have been shown to help maintain a youthful epigenetic state. Somatic cells that 
undergo reprogramming back to a pluripotent state shift their metabolism from being 
highly respiratory, which depends on mitochondria for ATP production, to a highly 
glycolytic [127]. Interestingly correlations have been made with genome methylation 
status and physiological/chronological age, known as the methylation clock. This 
correlation shows that the physiological age of an organism can be predicted based 
on the methylation status of its genome [142,143]. This suggests that altering 
metabolism could be a therapeutic option when dealing with age associated 
diseases and may hint to a link between the metabolism and transcriptome changes 
we see in chapter 4. Rapamycin is an FDA approved drug with a long record of 
clinical use and a relatively low rate of side effects. Methionine restriction on the 
other hand is a bit trickier. Adjusting a patients diet may help by controlling 
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methionine levels in patients is no easy task. For this reason it is important to further 
elucidate the mechanisms by which metabolism can be changed to provide optimal 
epigenetic maintenance and senescence abrogation. 
 
5.2 FUTURE DIRECTIONS 
5.2A Mitochondria and neurocognition 
Though this thesis work has contributed significantly to our understanding of 
NRTI toxicity, mitochondrial genetic predisposition and potential therapeutics, there 
are still more studies that can be done to further our understanding. One future goal 
for this work would be to recruit more HIV-1 patients for more robust statistics when 
correlating mtDNA with HAND susceptibility. Additionally a longitudinal study would 
be beneficial in continuing to understand how mtDNA background can predict an 
individual’s likelihood of decline overtime. A potential addition to the study would be 
to look for mtDNA correlations with parameters outside neurocognition like 
inflammatory markers, which are known to effect cognition and are key components 
that can drive aging. A study done by Dr. Hulgan’s group at Vanderbilt reported that 
a subset of HIV-1 patients on cART with no detectible plasma HIV RNA levels 
displayed a trend where haplogroup H had lower TNF-alpha levels[144]. This study 
suggests that different haplogroups could affect or be affected by inflammatory 
markers to varying degrees. Our prediction would be that those with higher 
neurocognitive scores would have less inflammation and would be part of a less 
susceptible haplogroup.  
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Another potential future direction would be to develop cybrid models to 
closely evaluate the SNPs that are unique to the L3e individuals and the L2a 
individuals. The goal of this study would be to evaluate different mitochondrial 
haplogroups in the context of the same nuclear background to better understand 
the cellular effects of specific mtDNA variants. Our prediction would be that L3e 
cybrids would display better cellular functioning than that of L2a cybrids. Further, 
specific cybrids with a single point mutation could be evaluated to better understand 
the functional consequences of a single SNP, like those listed in Figure 2.6 A. 
These cybrids could also be use to see if NRTI toxicity in-vitro is altered with 
different mtDNA backgrounds. This data would help to further identify individuals at 
greater risk for NRTI toxicity and HAND development. Our prediction would be that 
L3e mtDNA variants would fair better when stressed with NRTIs than L2a mtDNA 
variants due to the results from chapter two where L3e individuals had better motor 
scores and L2a individuals had lower working memory scores. 
More work can be done to evaluate super-complex formation in the context of 
the NRTIs. We see alterations in ETC efficiency, so determining if there is a 
disruption in super-complex formation might be extremely informative. Further 
identifying if therapies like rapamycin and methionine restriction can prevent this 
disruption could also provide further insight. Cardiolipin is a lipid that is found and is 
unique to the inner-mitochondrial membrane and has been shown to help with 
super-complex formation. Evaluating cardiolipin levels in the context of NRTI 
treatment and under different therapeutic treatments might also be informative. 
Therapeutics that interacts with and protects cardiolipin, like SS-31, already exist 
and may be beneficial to evaluate in this context [122]. 
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5.2B Intervention analysis and gene expression 
In terms of future work to be done on elucidating the therapeutic mechanisms 
of rapamycin, methionine restriction and the combination, there remains an 
enormous amount of differential expression analysis that can be done to thoroughly 
parse out the mechanisms unique to each treatment alone. To understand the 
global gene expression changes we see with the combination it would be useful to 
perform an epigenetic analysis and identify genes with different methylation status. 
To verify the role of the methyltransferases overexpressed in the combination, in 
depth analysis of telomeres would need to be performed. As previously discussed, 
these enzymes play a role in telomere protection and chromatin structure. This 
analysis would include evaluating TIFs as well as telomere length and verifying 
TERRA expression by PCR. Additionally, we would like to use telomere-binding 
oligos that are known to disrupt telomere stability to see if combination treated cells 
can handle telomeric stress more effectively. And finally over/under expressing the 
methyltransferases in-vitro to see how their expression affects cellular lifespan and 
senescence. 
These future studies display a unique opportunity to elucidate the impact of 
mitochondrial genetics on cellular and organismal function as well as to understand 
novel mechanisms for senescence reprograming. These findings create the 
potential to formulate novel therapeutic targets for the treatment of age related 
disorders as well as development of preventative medicine for at risk 
demographics.  
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CHAPTER 6: METHODS 
 
Patient DNA preparations 
DNA was isolated from PBMC (peripheral blood mononuclear cells) using 
Qiagen extraction methods, as described by the manufacturer. Mitochondrial DNA 
was then amplified from total DNA using mitochondrial genome specific primers and 
utilizing long-range PCR procedures as described by the manufacturer (Qiagen) 
[145]. mtDNA was amplified in three overlapping fragments. Fragment loci: 6511-
10622, 6739-16488, 151-10360. After amplification small amounts of PCR product 
were run on an agarose gel to confirm proper single band amplification, and PCR 
products were then purified using a Qiagen PCR clean up kit. Purified mtDNA 
fragments were quantified using Nanodrop 1000. For each patient the three 
amplified mtDNA fragments were pooled at equi-molar concentrations prior to 
sequencing library construction. 
 
mtDNA Sequencing 
Pooled mtDNA amplicons for each patient were converted to sequencing 
libraries using Nextera XT prep procedures for tagmentation, amplification and 
purification as specified in Illumina protocols. Sequencing preps were validated 
using a bioanalyzer (Agilent 2100 Bioanalyzer) and quantified using a fluorometer 
(BioTek instruments INC. FLx800) with the Quant-iT dsDNA Assay procedures as 
described by the manufacturer (Invitrogen). Processed patient mtDNA libraries were 
then pooled and sequenced using either MiSeq (2x150 nt paired ends) or NextSeq 
(2x150 nt paired ends) specifications (Illumina). 
  
102
 
mtDNA Data Analysis 
Raw data processing and demultiplexing of NextSeq data used bcl2fastq 
(MiSeq provided FastQ automatically). BWA-MEM (v0.7.10) was used to align 
sequencing reads to the revised Cambridge reference sequence (rCRS) [146]. 
Samtools mpileup (v0.1.19) and bcftools (v2.22.0) were used for variant calling 
[147]. GATK (v3.3-0) was used to compile consensus FASTA sequences for each 
patient [148]. Haplogroups were assigned using FASTA files uploaded to the 
Haplofind.unibo.it website[86]. R-Studio (v0.98.1091) and SPSS (v22) were used for 
statistical analysis and further data manipulation. Specific R packages used include 
SNPRelate for PCA analysis of genomic data [149-151].  
 
Data deposition 
Chapter 2 sequence data were deposited at the NCBI SRA under BioProject 
SRA accession: SRP074574 as BAM files. Chapter 3 sequence data were deposited 
at NCBI SRA under BioProject SRA accession: SRP104418 as BAM files. 
 
Drexel Medicine CNS AIDS Research and Eradication Study (CARES) 
Cohort 
To date, 557 HIV-1-infected patients were recruited from the Philadelphia 
area to the Drexel Medicine CNS AIDs Research and Eradication Study (CARES) 
cohort (Drexel University College of Medicine IRB protocol number 1201000748, 
Principal Investigator, Brian Wigdahl). All patient samples were collected under the 
auspices of protocol 1201000748 through written consent. The work described in 
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this manuscript was specifically reviewed and approved by the Drexel University 
Institutional Review Board. This cohort follows patients longitudinally, and to date 
there are 2179 total visits. 194 patients were administered a comprehensive 
neuropsychological evaluations, and of those patients a sub-cohort of 157 patients 
were subjected to full mtDNA sequencing [aged 26-73 (M = 51.52, SD = 8.06), 
including 105 men (68.1%)]. Participants were predominantly self identified African-
American (N = 145, 92.4%), with an average duration of infection of 18.79 years (SD 
= 7.72). Nearly all participants were being treated with cART at the time of visit 
(~95%), were clinically stable, had undetectable viral load (<20 copies/ml; 64%) and 
had a mean current CD4 of 673.48 cells/ul (SD = 364.34). Demographic information 
for this sub-cohort is displayed in Table 2.1. 
 
Neurocognitive Assessment/ Principal Component Analysis (PCA) 
Neuropsychological performance was assessed with nine variables from 
seven tests selected for their strong psychometric properties, their validity in 
detecting HIV-associated neurocognitive disorders (HAND), and the availability of 
demographically appropriate norms. All raw test scores were converted to 
demographically corrected T-scores (mean= 50; standard deviation= 10) using 
published normative data stratified by age, education, gender, and population group 
/ethnicity with higher scores indicating better performance [84,85]. In each figure, the 
T-score mean of 50, which reflects average-level performance, is represented by a 
red dotted line. 
 
Psychomotor speed and dexterity 
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 Grooved Pegboard Test  [85,152]   
On this test participants were asked to pick up odd-shaped pegs and fit them 
into corresponding holes.  The dependent variable was time to completion for all test 
items averaged for both the dominant and non-dominant hands. 
 
 Trail Making Tests- Parts A and B [85,153]   
For Trail Making Test- Part A participants were asked to draw a line 
connecting numbers from 1-22. For The Trail Making Test- Part B participants were 
asked to draw a line alternating between numbers and letters (e.g., 1-A-2-B).  Two 
dependent variables were obtained--time to completion for Part A and time to 
completion for Part B. 
 
Declarative memory 
Brief Visuospatial Memory Test – Revised [85,154]   
 Participants were shown a page consisting of six geometric figures for 10 
seconds and are asked to draw the figures from memory immediately or after a 20 
minute filled delay.  Three immediate free recall test trials were administered 
followed by a long free recall test trial and drawings were assigned points for 
accuracy. Two dependent variables were obtained, including the total number of 
points obtained on the three immediate free recall trials and the total number of 
points obtained on the delay free recall trial. 
 
Spanish and English Neuropsychological Assessment Scales (SENAS) Verbal 
Serial List Learning Test [84]   
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This test consisted of a 12-word list.  Five immediate free recall test trials 
were administered followed by a delay free recall test trial. A single dependent 
variable was obtained for the total words recalled across the five immediate free 
recall test trials and the delay free recall trial.       
 
Executive control/ working memory 
 SENAS Letter Fluency Test [84] 
 On this test participants were given 60s to generate words that begin with the 
letters ‘F’ and ‘L’ excluding proper nouns. The dependent variable was the total 
words recalled.  
 
 SENAS Semantic Fluency Test [84] 
On this test participants were given 60s to generate the names of animals. 
The dependent variable was the total number of correct responses. 
 
SENAS Working Memory Index [84]   
The SENAS Working Memory Index includes four tasks: 1) Digit Span 
Backwards- participants are read a series of numbers to repeat in reverse order; 2) 
Visual Span Backwards – participants point to dots on a page in reverse order from 
that presented by the examiner; 3) List Sorting I – participants are read a list of 
animals and fruits that they must repeat back in order of size, from smallest to 
largest; 4) List Sorting II- participants are read a list of animals and fruits that they 
must repeat back first by category and then in order of size (i.e., fruits first, sorted 
from smallest to largest, and then animals in order from smallest to largest). The 
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dependent variable is the total number of correct trials summed across all four tasks.  
 
Global Deficit Score 
The Global Deficit Score (GDS) was calculated to reflect overall level of 
cognitive impairment. Each of the nine test scores was transformed to a score 
ranging from zero to five as follows: T scores >40 = 0 (no impairment); T score 35-
39 = 1; T score 30 – 34 = 2; T score 25 – 29 = 3; T score 20-24 = 4; T score < 19 = 5 
(severe impairment). Transformed scores were averaged into a total GDS, with 
higher scores reflecting greater overall impairment [155].   
 
Statistical Analyses-Chapter 2 
In addition to the calculation of the GDS, the nine neuropsychological 
variables were reduced to three neuropsychological composite scores (psychomotor 
speed/dexterity; declarative memory; working memory/executive control), l debased 
on the results of a PCA (see results section). The three neuropsychological 
composites were analyzed in conjunction with mitochondrial haplogroup to assess 
relationship to neuropsychological functioning. Initial haplogroup analysis used the R 
package, SNPRelate to perform a PCA on the mitochondrial genomic data. 
Haplogroup information from Haplofind was then used as an input to color code 
individual patient samples. After assigning haplogroups and breaking the L 
haplogroups further into subgroups seven sub-haplogroups reached a minimum 5% 
frequency threshold within our study population and therefore were included in 
subsequent analyses (44). Kruskal-Wallis tests were used to examine differences 
between haplogroups on the three neuropsychological composite scores due to 
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unequal sample sizes. Mann-Whitney U tests were used to compare each sub-
haplogroup to the remainder of the cohort. Finally, stepwise linear regression was 
performed using SPSS and included the following independent variables: all sub-
haplogroups that represent at least 5% of the cohort input as binary variables (L1b, 
L1c, L2a, L3b, L3d, L3e and Non-Ls), years on cART, years since diagnosis, age, 
and gender. Three separate stepwise linear regressions were performed for each 
neuropsychological composite score/dependent variable: psychomotor speed and 
dexterity, declarative memory, executive/ working memory. 
 
Cell culture and cell culture reagents 
 Human cardiac fibroblast cells (Cell Applications INC. Cat #306-05F) were 
cultivated in Minimal Essential Medium (MEM) supplemented with 10% fetal bovine 
serum according to standard culture protocols [134]. Parallel sets of cultures were 
maintained in identical growth medium with the addition of 1nM rapamycin (Enzo 
Biologicals).  Cells were treated with or without rapamycin for two weeks prior to 
treatment with NRTIs. Rapamycin at a concentration of 1 nM has been shown to 
extend replicative lifespan and improve the mitochondrial profile in human fibroblasts 
[43,156]. Cell culture reagents were from Cellgro, unless otherwise indicated. 
Cells were exposed to NRTIs at the indicated concentrations (generally 10-20 
μg/ml) for 7 days. Culture medium with NTRIs was changed on Day 4. Mitochondrial 
measurements, bioanalyzer assessments, immunoblotting for protein expression 
and phosphorylation status, and assays for senescence were performed at the end 
of the 7-day culture period, unless otherwise indicated. 
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FTC and TDF were kindly provided by the NIH AIDS Research & Reference 
Reagent Program. The pharmacologic inhibitors PD98059 (10 μM, Santa Cruz 
Biotechnologies), BI-D1870, GW5074, and SB203580 (10 μM, Enzo Biologicals) 
were added to the culture medium during the final 48 hours or the final 2 hours of 
NRTI exposure, depending on the experiment. Mito-Q (20 nM) and TPP (20 nM) 
were kindly provided by Dr. Brett Kaufmann at the University of Pennsylvania School 
of Veterinary Medicine and were added to the culture throughout the NRTI exposure 
period.  
For metR studies, cells were cultured in methionine-free Dulbecco’s Modified 
Eagle Medium supplemented with 10% fetal bovine serum, 1% L-glutamine, and L-
methionine at 30 mg/L (standard concentration), 3 mg/L (90% metR), or 1 mg/L 
(97% metR). Parallel sets of cultures were maintained in identical growth medium 
with the addition of 1nM rapamycin (Enzo Biologicals). 
 
Western blotting  
Cell protein extracts were prepared by extracting with RIPA buffer containing 
a protease inhibitor cocktail (Sigma-Aldrich) and protein concentration was 
quantified using a bicinchoninic acid (BCA) assay (Pierce Biotechnology). Western 
blot analysis was performed using 15 to 30 μg of protein extracts run on SDS-PAGE 
and transferred onto nitrocellulose (Biorad) membranes. Blots were incubated with 
antibodies specific for: beta-actin (A2066 Sigma-Aldrich), TFAm (a kind gift of Dr. 
Brett Kaufmann, University of Pennsylvania), parkin (H300) sc-30130, p16 (JC8) sc-
56330, (Santa Cruz Biotechnologies) p53 (Ab-6) OP43, p21 (Ab-1) OP64, HDM2 
(SMP-14) sc-965  (EMD Millipore), phospho(S235/236)-ribosomal protein S6 (2211), 
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ribosomal protein S6 (54D2) 6194, phospho(S166)-HDM2 (3521S), phospho(S473)-
AKT (D9E) 4060S, AKT (C67E7) 4691S, beta-tubulin (10376), phospho(S82)HSP27 
(2401S), eEF2 (2332S) (Cell Signaling), IL-6 (A0286, NeoBiolab), lamin B1 
(ab16048), PINK1 (ab23707), and Mitoprofile Total OXPHOS Cocktail 
(MS6041/G2830, complex I-NDUFB8 subunit, CII-SDHB subunit, CIII-UQCRC2 
subunit, and CIV-mitochondrial COX1 subunit) and catalase (ab15834) (Abcam) 
according to manufacturers' instructions. Western blots were visualized using IRDye 
680 and 800 LI-COR secondary antibodies on a LI-COR Odyssey using LI-COR 
Odyssey software version 3.0 (LI-COR Biosciences).  
 
Mitochondrial membrane potential and mitochondrial ROS assessments 
Assessment of mitochondrial membrane potential and mitochondrial ROS, 
were made using flow cytometry. Mitochondrial membrane potential was detected by 
incubating the cells with 25 nM TMRE (Molecular Probes). Mitochondrial superoxide 
anion levels were detected by incubating the cells with 5 μM MitoSox Red (Molecular 
Probes. For the aforementioned assessments, incubation was performed at 37°C in 
5% CO2 for 30 minutes and cells were harvested in 2.5% trypsin-EDTA with serum-
containing medium. Cells were immediately analyzed by flow cytometry using a 
Guava EasyCyte Mini using the Guava Express Plus program (Guava 
Technologies).  
 
Oxygen consumption measurements 
Oxygen consumption was measured on a Seahorse XF24 Bioanalyzer 
(Seahorse Bioscience, using the XF cell mito stress test kit). Cells were seeded at a 
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density of 15,000 cells per well in an XF24 microplate. Following acquisition, results 
were normalized to cell number as analyzed on a Guava EasyCyte Mini (Millipore). 
Plates were loaded into the Bioanalyzer, which was pre-loaded with the sensor 
cartridge containing oligomycin, carbonilcyanide p-triflouromethoxyphenylhydrazone 
(FCCP), and rotenone/antimycin A. Oxygen consumption was measured in triplicate 
prior to and following sequential addition of oligomycin, FCCP, and 
rotenone/antimycin A. Respiration rates and proton leak were assessed as outlined 
in published methods [157]. Mitochondrial respiration was calculated based upon 
oxygen consumption rate measurements in triplicate. Basal respiration represents 
the initial oxygen consumption rate, while maximal respiration represents oxygen 
consumption following FCCP addition. ATP-linked respiration represents the 
oligomycin-sensitive oxygen change to basal oxygen consumption rate. Proton leak 
represents the oligomycin-insensitive oxygen consumption rate. Non-mitochondrial 
sources of oxygen consumption were subtracted by normalizing to the 
rotenone/antimycin A-insensitive oxygen consumption rate measurements. All data 
were normalized to cell number by counting cells in each well at the completion of 
the mitochondrial assessments.  
 
Senescence-associated beta-galactosidase (SA-β-gal) detection and 
telomere length assay 
Assessment of SA-β-gal activity was performed by plating cells following 
respective treatments at low density (0.5x 104/cm2) to prevent false positive staining, 
which is known to occur at high density. Cells were seeded after one week of NRTI 
treatment and stained 24 hours after seeding. Cells were washed with PBS, fixed 
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with 2% formaldehyde-0.2% glutaraldehyde for 5 minutes at room temperature, 
washed with PBS once more, and incubated overnight at 37°C in a staining solution 
containing 50 mg/ml X-gal, 100 mM potassium ferricyanide, 100 mM potassium 
ferrocyanide, 5 M NaCl, 1 M MgCl2, and 0.2 M citric acid/phosphate buffer (pH 6.0). 
Following incubation, cells were washed three times with PBS and at least 500 cells 
were counted for each sample in triplicate. Positive cells (blue) are expressed as the 
percentage of total cells. 
 
Rho-0 mtDNA experiment 
Cultures were exposed to ethidium bromide in full growth medium 
supplemented with 50 ug/ml uridine and 1mM sodium pyruvate containing the 
indicated concentrations of ethidium bromide indicated in each experiment [158]. For 
the ethidium bromide treatment, cells were seeded at a standard density (1x104/cm2 
) according to a protocol established for the cultivation of human mesenchymal cell 
cultures [159]. Ethidium bromide containing medium 24 hours post seeded to ensure 
that the drug did not alter cell attachment. Cultures were exposed to ethidium 
bromide containing medium for 7 days with one change of medium. Mitochondrial 
DNA was extracted using phenol-chloroform extraction based upon published 
analysis of methods for the optimal extraction of mitochondrial DNA [160]. Total DNA 
was extracted using phenol/chloroform extraction using the phase-lock gel system 
(5Prime Inc. Gaithersburg, MD) followed by ethanol precipitation and a second 
phenol/chloroform extraction. Total DNA was quantified using a nanodrop 
spectrophotometer. Primers used to amplify mitochondrial and nuclear DNA targeted 
the mitochondrial leucine t-RNA transcript and the nuclear beta-2 microglobin gene 
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locus. Primer sets were as follows: for leucine t-RNA, 5'-
CACCCAAGAACAGGGTTTGT-3' and 5'-TGGCCATGGGTATGTTGTTA-3': for beta-
2 microglobulin, 5'-TCTCTGCTCCCCACCTCTAAGT-3"and 5'-
TGCTGTCTCGATGTTTGATGTATCT-3'. Quantitative real-time PCR was performed 
using the Verso Sybr 1 step qPCR kit (Thermo Scientific, Waltham, MA) in a 
Stratagene Mx3000P thermocycler. 
 
Statistical Analysis- Chapter 3 
Results are representative of at least three independent experiments and 
statistical significance was determined using an unpaired two-tailed Student’s t-test. 
Data sets were subjected to normality tests to verify normal distribution of data. One-
way Anova with Bonferroni post-hoc analysis was performed on multiple comparison 
groups involving control, NRTI, rapamycin/methionine restriction, and 
rapamycin/methionine restriction NRTI, where appropriate. 
 
RNASeq: RNA extraction, cDNA synthesis, and sequencing 
Total RNA was isolated from triplicate samples of Human Cardiac Fibroblasts 
(Early Passage, Late Passage, Methionine Restricted, Rapamycin treated and 
Combination treated) using Trizol extraction methods. Total RNA was submitted to 
the Drexel University College of Medicine Center for Genomic Sciences (DUCOM 
CGS) for quality control, polyA selection, cDNA library preparation, and sequencing. 
The cDNA library was prepared using the TruSeq Stranded mRNA Prep Kit 
(Illumina), and was sequenced using the Illumina NextSeq 500 platform over two 
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runs with 75 cycle High Output kits (ver. 1). Total RNA was also used for nanostring 
analysis counts from this experiment were analyzed using nCounter software.  
 
Mapping of RNA-seq reads 
For read alignments, the GRCh37.75 reference was used. The following 
alignment algorithms were used to map all samples to the reference. Specifically, 
the Burrows-Wheeler Aligner mem algorithm (BWA, v0.7.10) and the STAR aligner 
(v2.4.0h), in conjunction with downstream analysis tools to independently arrive at a 
set of differentially expressed genes. Importantly, only uniquely mapping reads were 
retained by filtering with Sambamba (v0.5.0) using a mapping quality of ≥1 for BWA, 
255 for STAR. General mapping statistics were generated using the Sambamba 
flagstat tool or by the STAR aligner. 
 
Generating count tables 
A series of Bioconductor packages for R were used to create count tables 
reporting the number of reads mapping to each transcript in the reference gene set 
using either the BWA or STAR alignments. Specifically, these packages were 
RSamtools (v1.18.2), GenomicFeatures (v1.18.3), and GenomicAlignments (v1.2.1). 
The output of this workflow was a data table with counts per annotated gene per 
sample, suitable for direct use in the differential expression analysis. In addition, 
counts per gene were normalized using the reads per kilobase of gene per 
megabase library size (RPKM) method by dividing total counts aligned to each gene 
by the kilobase length of that feature and the total number of millions of reads in the 
sample.  
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Differential gene expression analysis 
While independent differential gene expression analyses were tested, the 
majority of differential gene expression analysis was done using the DESeq2 
(v1.6.3) package in R [161]. Individual contrasts were conducted within the DESeq2-
generated object on raw counts normalized by the median ratio method, and 
statistical significance was determined after multiple testing correction and 
calculation of fold changes based on a fitted model of normalized counts. For this 
analysis, significant differential gene expression was determined using an FDR 
adjusted p-value of 0.05 (adjusted with the Benjamini-Hochberg adjustment). Venn 
diagrams were generated using R VennDiagram package[162]. Additional data 
visualization was done using R, including the ggplot2 package (v1.0.0) [163]. To 
follow general convention, and to give an estimated idea of expression levels, 
plotting was done using RPKM values, however, statistical significance was 
generated using the median ratio normalized values within DESeq2. PCA plotting, 
MA plot and SDM were all plotted as described on the bioconductor RNAseq 
workflow[164]. 
 
Pathway analysis and gene ontology 
DAVID pathways analysis was used for pathway enrichment and gene 
ontology analysis. Gene lists created through DESeq2 thresholding were feed into 
DAVID functional annotation tool in order to provide KEGG pathway correlations and 
rank important genes involved in the given pathway[165]. 
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TERRA Analysis 
For RNASeq interrogation of TERRA expression fastq files were read using 
the unix command awk and the pattern “ttaggg” was searched for. The repeat 
needed to be present 4 times in a row for the read to count as a TERRA read. In 
addition it is important to note that the probability of the repeat happening 4 times 
consecutively by random chance is 1 in roughly 280 trillion (424). For dot blot 
analysis 1ug of RNA was added to a nylon membrane and UV cross-linked. 
Membrane was incubated with a P32 end-labeled probe for either TERRA 
(CCCTAA)4 or 28S rDNA (GGTCTAAACCCAGCTCACGTTCCC) oligonucleotide as 
a loading control [137].  
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